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                                    Abstract 
Bordetella bronchiseptica colonizes the upper respiratory tract of a wide variety 
of mammals and is involved in diseases such as kennel cough in dogs, atrophic 
rhinitis in pigs and upper respiratory tract infections of laboratory animals. Studies 
were focused on developing a heterologous antigen expression system in B. 
bronchiseptica and to evaluate the potential of this organism as a candidate mucosal 
vaccine vector. Since the role of Bordetella bronchiseptica and Pasteurella multocida 
toxin (PMT) in the disease atrophic rhinitis of pigs was well documented, this 
research was focused in the possibility of developing a refined vaccine to control this 
disease. A promoter region related to heat shock protein genes was identified using a 
green fluorescent protein reporter system. This promoter drove high- level expression 
of GFP compared to a tac promoter or B. bronchiseptica fim N gene promoter. A non-
toxic protective P. multocida toxin fragment and GFP were expressed in B. 
bronchiseptica in a broad-host-range plasmid vector PBBR1MCS2 under the control 
of the promoter region identified. Colonization kinetics, plasmid stability, and 
immune responses generated following intranasal inoculation of recombinant B. 
bronchiseptica were evaluated. While wild type and recombinant B. bronchiseptica 
colonized the mouse respiratory tract effectively, the plasmid was completely lost 
from the organism after 72 hours post- inoculation. After a single intranasal 
inoculation, B. bronchiseptica specific IgM, IgA and IgG responses were detected in 
serum and respiratory lavage. However, PMT-specific antibodies were not detected. 
Four intranasal inoculations with  B. bronchiseptica expressing green fluorescent 
protein (GFP) induced a GFP-specific systemic and mucosal immune response, while 
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similar inoculations with B. bronchiseptica expressing PMT fragment did not induce 
a PMT-specific immune response.  
This study also evaluated the immune response to a chimeric protein generated 
by combining a gene fragment encoding neutralizing epitopes of Mannheimia  
haemolytica leukotoxin and a fimbrial protein gene (fim N) from B. bronchiseptica. 
Immunization of mice with the recombinant chimeric protein elicited a significantly 
stronger anti- leukotoxin antibody response than comparable immunizations with 
fusion proteins lacking FIM N. The chimeric protein exhibited more stability. 
Leukotoxin is an important virulence factor in shipping fever pneumonia in feedlot 
cattle and is a critical protective antigen. This chimeric protein may be a candidate for 
inclusion in new generation vaccines against shipping fever pneumonia. The results 
of these studies strongly support the potential for developing B. bronchiseptica as a 
candidate mucosal vaccine vector and FIM N as a carrier protein for heterologous 
antigens. 
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 Introduction 
      Bordetella bronchiseptica is an upper respiratory tract pathogen, which infects a wide 
variety of host species including domestic, laboratory and wild animals and may also 
opportunistically infect human beings [33, 60]. B. bronchiseptica is involved in diseases 
such as kennel cough in dogs, and atrophic rhinitis in swine [60]. This organism is an 
adept colonizer of the upper respiratory tract of mammals and colonization is 
characterized by attachment to the ciliated epithelium [6, 7, 8, 9]. The attachment is 
achieved by the expression of adhesins such as fimbriae, filamentous haemagglutinin and 
pertactin [33, 81, 147].  
Atrophic rhinitis is an upper respiratory tract disease of pigs characterized by 
degeneration and atrophy of nasal turbinate bones in market weight hogs, leading to 
visible distortion and shortening of the snout [20, 60, 67, 165, 169]. The infection with B. 
bronchiseptica leads to a mild reversible form of atrophic rhinitis, whereas, infection with 
Pasteurella multocida leads to a severe progressive form of atrophic rhinitis [1, 113, 165 
166].  Toxins produced by B. bronchiseptica and Pasteurella multocida are involved in 
this disease condition [36, 37, 48, 49, 50, 91, 92, 93]. Dermonecrotic toxin produced by 
virulent strains of B. bronchiseptica can induce impaired osteoblastic differentiation and 
atrophic rhinitis in pigs, rabbits and mice [104, 113].  
Pasteurella multocida is an important veterinary pathogen involved in diseases such 
as atrophic rhinitis in swine, fowl cholera in birds, hemorrhagic septicemia in cattle and 
other respiratory diseases in lab animals [20, 21]. Pasteurella multocida toxin (PMT) 
produced by capsular type D or type A strains of P. multocida is a major virulence factor 
in atrophic rhinitis [40, 148, 149, 184]. This toxin is a potent, intracellular, heat labile, 
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146kD protein that induces bone resorbtion through increased osteoclastic and impaired 
osteoblastic activity [66, 91, 92, 93, 98, 115, 116, 146, 151, 166]. It also causes 
degeneration and necrosis of liver, pneumonia, spleenic atrophy, orchitis and 
proliferation of bladder epithelium in experimental animals [48, 49]. PMT triggers a 
number of signal transuduction pathways leading to cytoskeletal rearrangement [182, 
195]. The role played by P. multocida and B. bronchiseptica in atrophic rhinitis is well 
documented [34, 36, 37].  A mutualistic disease-causing relationship exists between these 
two organisms [34, 36, 37].  Colonization with B. bronchiseptica predisposes animals to 
infection with P. multocida, which may lead to a severe atrophic rhinitis and financia l 
losses in the swine industry [1, 20]. PMT, itself, can also lead to a severe form of atrophic 
rhinitis when inoculated into experimental animals [48, 49].  
      Atrophic rhinitis vaccines initially consisted of different preparations of killed or live 
avirulent B. bronchiseptica. After elucidating the role of PMT in atrophic rhinitis, the use 
of PMT toxoid or non-toxic recombinant derivatives provided a significant degree of 
protection from PMT induced atrophic rhinitis and now most vaccines consist of B. 
bronchiseptica bacterin/ live attenuated vaccines and P. multocida bacterin and toxoid  
[12, 48, 49, 89, 142, 184].  
Considering the synergistic role of B. bronchiseptica and P. multocida in atrophic 
rhinitis, further development of combined vaccines seems to be a rational approach to 
control this disease. A mucosal immune response to B. bronchiseptica will lead to 
immunological elimination of B. bronchiseptica thus preventing colonization with P. 
multocida and other respiratory pathogens. Anti-PMT-antibodies will reduce the 
incidence of PMT-induced atrophic rhinits. 
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The mucosal surfaces are the portals of entry of many pathogens and they constitute 
the first lines of defense against pathogens [118, 119]. Attachment properties of B. 
bronchiseptica could be effectively utilized to deliver heterologous antigens to the 
respiratory tract for the purpose of inducing protective mucosal immune responses 
against respiratory pathogens. 
      The major goal of this study was to explore the possibility of B. bronchiseptica as a 
candidate mucosal vaccine vector.  
Specific aims of this study were: 
1. To identify and isolate a constitutive promoter from B. bronchiseptica    
using a green fluorescent protein reporter system. 
              2.    To clone and express a non-toxic P. multocida toxin fragment under the   
control of a suitable promoter. 
        3.    To study colonization, plasmid stability and antibody response following 
intranasal inoculation with B. bronchiseptica expressing the PMT 
fragment. 
4.   To evaluate the efficacy of Fim N protein of B. bronchiseptica as a 
carrier protein for heterologous antigens. 
The Genus Bordetella 
      Bordetellae are small, gram negative, aerobic, non-acid fast, non-spore forming 
coccobacilli [81, 147, 150]. All species of Bordetella are asaccharolytic [81, 147, 150]. 
They utilize amino acids and other organic acids as sources of energy [81, 147, 150]. 
Their optimum temperature for growth is 35-37oC. The members of this genus are B. 
pertusiss, B. parapertussis, B. bronchiseptica, B. avium, B. hinzi, B. holmesii,  
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B. trematum and B. petrii [33, 81, 147, 150].  All the members of this genus are catalase 
positive.  B. pertussis is the most fastidious species within the genus, and does not grow 
on simple media [81, 147, 150]. Other Bordetella species are less fastidious except B. 
parapertussis and B. holmeseii, which are relatively slow growing [81, 147, 150].  Nitrate 
reduction, urease, oxidase and motility tests can be utilized to differentiate species [81, 
147, 150]. The members of this genus are closely related, genetically, and their DNAs 
have a G+C content of 60.2 -70% [147].  
      B. pertussis is strictly a human pathogen responsible for whooping cough in 
children,and pertussis in adolescents and elderly humans [33, 147, 188]. This is an acute, 
highly contagious disease in children characterized by characteristic paroxysmal 
coughing.  B. parapertussis is also a human adapted pathogen and causes pertussis- like 
syndrome  in humans [81, 147, 150]. It has also been isolated from cases of chronic non-
progressive pneumonia in sheep [33, 147]. Bordetella avium is responsible for a 
condition known as coryza or rhinotracheitis in turkey poults and chickens [81, 147, 150].  
This disease condition is highly contagious and predisposes birds to secondary infections 
[87].  Bordetella bronchiseptica has been associated with acute tracheobronchitis or 
kennel cough in dogs and atrophic rhinitis in swine [6, 7, 8, 9, 60]. This organism can 
also cause upper respiratory tract infection of a wide variety of mammals such as mice, 
rabbits, guinea pigs, cats, and horses [60].  
      B. hinzii, has been isolated from the respiratory tract of  immunocompromised human 
beings, healthy turkeys, and chickens [81, 147, 150].  B. holmesii, has been isolated from 
human beings with respiratory tract infection and septicemia [81, 147, 150].  B. trematum 
has been  isolated from human beings with wound infections and otitis media [33, 81, 
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147, 150]. B. petrii, the new member of this genus, was isolated from an anaerobic 
bioreactor [191]; however, there is very little information available on this species. 
      The population structure of the Bordetella genus has been subjected to extensive 
evolutionary studies. The close phylogenetic relationship of Bordetella with Alcaligenes 
and other environmental bacteria suggests that the ancestral Bordetellae were free- living 
and evolved to infect warm-blooded animals [156]. The 16S ribosomal RNA analysis 
placed B. bronchiseptica as the nearest relative to bacterial endosymbionts in protozoa 
[156]. Musser et al. obtained an estimate of genetic relatedness of 60 strains of 
mammalian Bordetellae from worldwide sources by utilizing multilocus enzyme 
electrophoresis of 15 metabolic enzymes [137]. Van der Zee et al. also attempted to 
differentiate members of this genus by comparing the electrophoretic mobilities of 
metabolic enzymes [190]. Multilocus sequence typing based on sequencing of a portion 
of house keeping genes and insertion sequences were also utilized to compare the 
evolutionary relationship of members of the genus [61, 156, 190].  These studies 
concluded that B. pertussis, B. parapertussis and B. bronchiseptica are subtypes of a 
single genomic species. B. avium, B. holmesii, and B. hinzii each form true genomic 
species [190]. It was proposed that B. bronchiseptica may be the evolutionary progenitor 
and other species may be considered as host adapted lineages of B. bronchiseptica [61, 
156, 190]. The sequence comparison of genes encoding fimbrial subunits, adenylate 
cyclase toxin, pertactin, pertussis toxin and BvgAS, confirmed the close relationship 
between B. bronchiseptica and B. parapertussis and a more distant relationship between 
these species and B. pertussis [33, 190]. Also, human and sheep isolates of B. 
parapertussis comprise genetically distinct population [33, 190] 
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Gene regulation in Bordetella 
      Virulence gene expression in Bordetella spp is controlled by a two-component signal 
transduction system encoded by the Bordetella virulence gene (bvg) locus [187, 196, 
197]. Some of the virulence factors controlled by this system include fimbriae, 
filamentous haemagglutinin, pertactin, pertussis toxin, adenylate cyclase toxin and 
dermonecrotic toxin. The BvgAS system is a two component signal transduction system 
controlled by proteins, BvgS (a sensory transmembrane protein) and a transcriptional 
activator   BvgA (a cytoplasmic DNA binding protein) [33, 196, 197]. This locus is 
activated by temperatures above 37oC, and low sulfate or nicotinic acid concentrations 
resulting in expression of virulence factors [33, 196, 197].  
      A second set of genes is activated when the locus is shut down by low temperature 
(less than 30oC) or in the presence of increased sulfate or nicotinic acid concentration. 
Genes involved in flagella synthesis and urease expression [121, 131, 198] in B. 
bronchiseptica are negatively regulated by the bvg locus. However, in human isolates of 
B. parapertussis urease is repressed by bvg locus whereas in sheep isolates of B. 
parapertussis it is not under the control of bvg locus [33]. In some strains of 
B. bronchiseptica, genes involved in alcaligin biosynthesis are negatively regulated by 
the bvg locus [58]. In B. pertussis, five genes (vrg6, vrg18, vrg24, vrg53, vrg73) which 
involve a second intermediate regulatory locus, bvgR (a transcriptional repressor) were 
discovered [101, 126]. 
      Phenotypic modulation was described in earlier literature as the reversible loss of 
virulence-associated phenotypes that happens in response to changes in environmental 
conditions [196, 197]. Many of the earlier descriptions of the phases (phase I to phase IV) 
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were based on colony morphotypes. The virulence phase was called X mode (now known 
as bvg positive). X mode is seen at 37oC and in the presence of certain chemical ions such 
as sodium, potassium, halides, formate, and nitrate [33, 196, 197]. The avirulent phase, 
called C mode (now known as bvg negative) was seen at low temperatures and in the 
presence of ions such as sulfate and nicotinic acid [33, 196, 197]. Phase variation is the 
irreversible loss of virulent phenotype due to mutations occurring in the bvg-locus [33, 
196, 197]. In B. bronchiseptica, positively regulated traits (Bvg+) were required for 
respiratory infection. Whereas, negatively regulated traits (Bvg-) were required for 
surviving nutrient limitation [30].  
      A recent study described another phase called bvg intermediate phase (Bvgi), when B. 
bronchiseptica was grown in semi-modulating conditions [31]. This phase was 
characterized by the presence of one subset of bvg+ factors with the absence of other 
bvg+ factors and the presence of factors, which are exclusively expressed in this phase 
[31]. Isolates with Bvgi phenotypes displayed reduced virulence in a rat model of 
respiratory tract infection and increased ability to survive nutrient deprivation [31]. 
Stockbauer et al. described a protein called BipA, and its gene, which was exclusively 
expressed, in the Bvg intermediate phase [183]. A second two-component sensory 
transduction system called "ris"  has been described in B. bronchiseptica. This system had 
similarities to the bvg system and was up regulated at 37oC and down regulated at lower 
temperatures or in the presence of magnesium ions [90]. 
Bordetella virulence factors 
      Colonization of Bordetella in the upper respiratory tract of the host is mediated 
through strong attachment to the ciliated epithelium. A number of adhesins such as 
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fimbriae, filamentous haemagglutinin, and pertactin have been recognized. Heavy 
colonization with production of toxins like dermonecrotic toxin, adenylate cyclase, 
tracheal cytotoxin, pertussis toxin, and endotoxin will lead to inflammatory responses in 
the respiratory tract that may produce significant clinical disease [33, 147, 150]. Major 
virulence factors produced by members of the genus Bordetella are discussed below. 
      B. pertussis is known to produce pertussis toxin, which is the important virulence 
factor in whooping cough in children [141]. B. bronchiseptica and B. parapertussis also 
contain the pertussis toxin gene, but do not express pertussis toxin [2, 73]. This is due to 
the differences in sequences in the promoter region, which make the toxin inactive [73]. 
Replacement of the pertussis toxin promoter region in B. bronchiseptica and B. 
parapertussis with tha t of B. pertussis resulted in expression of active toxin [73]   
      Adenylate cyclase toxin (ACT) is a member of the RTX (repeat in toxin) family of 
bacterial toxins [59, 63]. RTX toxins are a family of pore-forming proteins of Gram- 
negative bacteria, which contain glycine-aspartic acid rich repeats [52]. This toxin has 
bifunctional activity as a hemolysin and adenylate cyclase toxin. Adenylate cyclase and 
hemolytic activity are separable [157]. ACT can enter eukaryotic cells through pore 
formation and become activated by calmodulin, which leads to the production of 
unregulated cyclic AMP levels [59, 63, 75, 114, 157]. ACT is a 216 kD secreted protein 
and is produced by all members of the Bordetella genus except B. avium [33, 147, 157]. 
The major differences in amino acid sequence of adenylate cyclase toxin between B. 
bronchiseptica and B. pertussis were located on the carboxy terminal repeat region of the 
molecule [10]. Harvill et al. studied wild-type and mutants of B. bronchiseptica with 
alterations in adenylate cyclase toxin and concluded that phagocytic cells are the primary 
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targets of this toxin [71]. ACT is unique among the RTX toxins; in that it has enzymatic 
activity as well as the capacity to form an ion-permeable pore in target cell membranes. 
The latter causes lysis of erythrocytes, which is a colony, associated phenotype that can 
be easily seen on Bordet-Gengou agar containing horse or sheep blood cells [75, 157]. 
ACT mutants were defective in colonization [71]. The protective nature of ACT 
antibodies against infection suggests that this toxin is required for initial colonization [59, 
97]. ACT down regulates the phagocytic activity of neutrophils and macrophages and can 
induce apoptosis in macrophages [10, 71]. The antigenic and protective properties of 
adenylate cyclase toxin of B. bronchiseptica are different from that of B. pertussis [10, 
75].  
      Dermonecrotic toxin (DNT) is a 162 kD, intracellular, dermonecrotic, thermolabile 
and mitogenic cytotoxin produced by Bordetella spp. [138, 154, 194]. DNT can impair 
osteoblastic differentiation and is an important virulence factor in atrophic rhinitis in 
pigs, rabbits and mice [104, 113, 162]. DNT is cytotoxic for Vero cells, embryonic 
bovine lung cells and bovine turbinate cells [83, 178]. It induces morphological changes 
in cultured fibroblasts, including the assembly of actin, stress fiber formation, focal 
adhesion assembly, multinucleation and is a potent mitogen [83, 104, 178]. DNT 
deamidates the Gln 63 residue of small G proteins like Rho, Rac and Cdc42 leading to 
their constitutive activation and polymerization of actin [83, 95, 178]. DNT shows 
structural and functional homology to Cytotoxic Necrotizing Factor I of E. coli and 
deamidation activity of both these toxins are mapped to their C- terminus [110]. 
      Tracheal cytotoxin (TCT) is a muramyl peptide released by Bordetellae, [74, 112] 
and is responsible for specific epithelial pathology in whooping cough. TCT stimulated 
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production of IL1 and formation of large amounts of nitric oxide result in damage to 
ciliated epithelial cells [33, 74, 112]. It has been suggested that TCT may also be 
involved loss of ciliary activity and colonization of the organism in the respiratory tract 
[9, 29]. 
      Pertactin (PRN) is an outer membrane protein, and a nonfimbrial adhesin that belongs 
to the family of autoexporters [22, 42, 109, 111]. Autoexporter/ autotransporters are 
proteins, which have the ability to export themselves to the outer membrane, cleave 
themselves via protease activity and release fina l product into the medium [70]. Pertactin 
was initially identified in B. bronchiseptica as a 68kD protein  [132]. It is a 69kDa 
protein in B. pertussis and a 70kD protein in B. parapertussis [22, 132]. Pertactin 
contains one RGD (arginine-glycine-aspartic acid) motif and several proline rich as well 
as leucine rich repeats involved in eukaryotic cell binding [33, 109]. Pertactin is also a 
protective antigen that is included in acellular pertussis vaccines. Although pertactin can 
function as a nonfimbrial adhesin and can induce a protective antibody response against 
Bordetella, its role in pathogenesis is unknown [33]. Recently genetic and phenotypic 
heterogeneity has been reported in strains of B. bronchiseptica and B. pertussis [135, 
158]. This variation, which occurs in the repeat sequence motifs, is believed to be due to 
antigenic drift occurring in immunized populations. 
      Other Bordetella proteins with predicted autoexport properties include Tracheal 
Colonization Factor [47] BrkA [45, 163] and Vag8 [46]. These proteins share amino acid 
sequence homology at their C terminus, contain RGD motifs and are detected only in B. 
pertussis. 
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      Filamentous haemagglutinin (FHA) is a high molecular weight, secreted outer 
membrane protein reported in B. bronchiseptica, B. pertussis, B. parapertussis [33, 86, 
145]. FHA is a major attachment factor and protective antigen in Bordetella [108]. There 
are important domains in FHA, including a RGD motif, a carbohydrate-binding site and a 
heparin-binding site [68, 153, 159, 160], which are involved in eukaryotic cell binding.  
The RGD sequence of FHA binds to the integrin, CR3, of macrophages, which may 
promote phagocytosis. Attachment of FHA to ciliated cells is mediated through the 
carbohydrate-binding domain [153, 159, 160]. The heparin-binding domains of FHA may 
help in low affinity binding of the bacteria to the extracellular matrix of the upper 
respiratory tract [68, 122]. FHA is highly immunogenic and antibodies to FHA prevent 
attachment of B. pertussis and B. bronchiseptica [86, 96]. FHA is also a good mucosal 
immunogen as evidenced by high levels of anti-FHA antibodies in infected individuals 
[33, 86, 96, 108, 152]. In one study, FHA enhanced the mucosal immunogenicity of 
liposome delivered antigen administered via intranasal route [152] 
      Cotter et al. suggested that, FHA mediated attachment to tracheal epithelium allowed 
Bordetella to overcome constitutive mucociliary mechanisms in the trachea [32]. FHA 
appears to be secreted in lower amount in B. bronchiseptica compared to B. pertussis [86, 
88, 108]. It was postulated that the different levels of FHA expression in these species 
might be due to differences in protein production, differences in cell envelope 
composition and structures that affect export from cells or degradation [88]. 
      Fimbriae produced by B. bronchiseptica species are important virulence factors 
which help in adherence and colonization of the bacteria to host tissues [99]. Fimbriae are 
heteropolymeric filamentous appendages that are involved in attachment of many Gram-
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negative bacteria. They are highly immunogenic, antigenically stable proteins that are 
included as components of many acellular vaccines [89]. Major fimbrial subunit genes of 
B. bronchiseptica are fim2, fim3, fimX, fimA and fimN [13, 17, 94, 133, 134, 172, 199, 
200]. The fimbrial proteins of B. bronchiseptica and B. pertussis are serologically cross-
reactive. Fimbrial biogenesis is a complex process involving a cluster of genes called 
fimABCD [85, 99]. These are located in the FHA operon immediately downstream to 
fhaB, the structural gene for filamentous haemagglutinin. A mutation in FimB can abolish 
the expression of fimbriae [117]. Major fimbrial subunit genes are located elsewhere in 
the chromosome [99]. Fim A encodes a major structural subunit that is nonfunctional in 
B. pertussis but is expressed in B. bronchiseptica [13]. Fim D, a minor fimbrial subunit 
produced by B. pertussis, is a putative adhesin and tip protein [57]. The sequence of fimD 
in B. bronchiseptica differs by only one base pair from that in  B. pertussis. Mutation in 
fimD blocks the expression of major fimbrial subunits suggesting that it may have 
chaperone like activity [57]. The propensity for frequent deletion or addition of bases in a 
cytosine-rich sequence within the Bordetella fimbrial promoter region is a proposed 
mechanism for fimbrial type-switching, a phenomenon which enables Bordetella to 
express one type, two types or no fimbriae at a given point of time [200]. This may be 
attributed to selective pressure driven by the host's immune response or there may be 
differences in host receptors that induce the expression of a particular fimbrial gene. 
Receptors for fimbriae contain sulfated sugars like heparin sulfate, which are ubiquitous 
in the respiratory tract [55, 56]. Sequences similar to the heparin-binding region of 
fibronectin have been evaluated in fim2 and fim3 subunits of B. pertussis [55, 56]. Studies 
on expression of B. pertussis fimbriae in E. coli revealed that a recombinant subunit 
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protein was immunonologically and antigenically distinct from the native fimbriae and 
exhibited limited cross reactivity [192, 193]. Quaternary structure generated by subunit 
interaction of the fimbrial protein may be necessary for its incorporation as a protective 
immunogen in vaccines. Fimbriae are required for establishment of persistent 
colonization of the trachea in mice and may play a role in the development of a humoral 
immune response to Bordetella infection [117]. 
      The products of Type III secretion systems are other newly identified factors involved 
in B. bronchiseptica virulence [206, 207]. Type III secretion allows Gram-negative 
bacteria to translocate molecules into the cytoplasm of eukaryotic cells [202]. These 
products interact with a variety of eukaryotic signal transduction pathways to promote 
bacterial-host interactions [202]. In B. bronchiseptica the type III secretion products are 
specially transcribed under Bvg+ conditions [206]. These products are highly 
immunogenic in rabbits and are required for in vitro cytotoxicity [33, 206, 207]. These 
products may also be expressed by B. pertussis and sheep isolates of B. parapertussis 
[33]. Yuk et al. investigated the functions of the type III secretion system in B. 
bronchiseptica by comparing the wild-type bacteria with two strains that were defective 
in type III secretion system [206, 207]. The mutants were defective in long-term 
colonization of the trachea in immunocompetent mice. Also, mutants induced high titers 
of anti-bordetella antibodies compared to wild-type. The authors suggested that type III 
secretion products interacted with components of innate and adaptive immune systems of 
the host and that these products were required for inducing apoptosis in macrophages in 
vitro and increasing the influx of inflammatory cells in vivo. This modulation of immune 
response may be achieved through inactivating NF-kB, a transcription factor for 
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regulation of genes involved in immune response [206]. Winstanley et al. investigated 
and confirmed the presence of a type III secretion system in animal isolates of B. 
bronchiseptica [201].  
      The lipopolysaccharide (LPS) molecules of members of the Bordetella genus differ in 
their structure [33].  B. pertussis contains a complex trisaccharide with no O antigen. 
Therefore, it is generally referred as lipo-oligosaccharide.  B. bronchiseptica has a 
trisaccharide plus an O- antigen repeat and B. parapertussis has an altered trisaccharide 
plus O-antigen-like repeat [72]. The wlb gene cluster, composed of 12 genes, is required 
for biosynthesis and addition of the trisaccharide in B. pertussis and B. bronchiseptica 
and O-antigen- like repeat in B. bronchiseptica and B. parapertussis [72]. Harvil et al. 
investigated the effect of mutation of wlb locus on colonization of B. bronchiseptica in 
the respiratory tracts of mice. They observed that biosynthesis of full length LPS, by 
these three Bordetellae are essential for virulence in mice [72]. However, LPS molecules 
of these species play different roles in infection [72]. Changes in LPS expression in B. 
bronchiseptica is controlled by BvgAS system [189]. When resistance profiles of B. 
bronchiseptica and B. pertussis to various antimicrobial peptides were tested, [4] B. 
bronchiseptica exhibited significantly higher resistance to antimicrobial peptides 
compared to B. pertussis.  The resistance in B. bronchiseptica was presumably due to the 
highly charged O-specific sugar side chains in its LPS [4]. It was suggested that antigenic 
polymorphism in the lipopolysaccharides from human and animal isolates of B. 
bronchiseptica may be due to differences in receptors of human and animal respiratory 
tracts [107].  
 16 
      Urease, a bvg repressed phenotype in B. bronchiseptica, has been another suggested 
virulence factor which may be involved in intracellular survival of this bacterium [120]. 
However, urease expression did not have any effect on the ability of B. bronchiseptica to 
colonize and persist in the mouse respiratory tract [121, 131]. 
Intracellular survival  
      Although B. bronchiseptica has been considered an extracellular pathogen, there have 
been a number of reports that demonstrate the intracellular survival of this organism. 
Guzman et al. demonstrated intracellular survival of B. bronchiseptica in mouse dendritic 
cells, in vitro and speculated that intracellular survival in natural infections caused by this 
organism, may lead to the chronicity of infection [62]. Intracellular invasion of B. 
pertussis was dependent on Bvg + phenotype and induction of apoptosis in macrophages 
was attributed to the adenylate cyclase toxin [5].  B. bronchiseptica induced macrophage 
killing by bvg -regulated factors [5]. Also, Bvg mutants of B. bronchiseptica showed 
significant survival advantage over wild type strains [5]. A study by Brockmeier and 
Register on intracellular survival and cytotoxicity of B. bronchiseptica in swine alveolar 
macrophages indicated that another temperature dependent regulatory mechanism, in 
addition to Bvg, may play a role in adhesion and intracellular survival of this organism 
[14]. However, cytotoxicity for swine alveolar macrophages was observed only in 
infection with virulent bvg+ strains [14]. The differential survival of B. pertussis and B. 
bronchiseptica in macrophages has been attributed to their differences in acid tolerance 
[179]. In contrast to B. pertussis, B. bronchiseptica is insensitive to an acidic PH as low 
as 4.5. The acidic environment of the phagolysosome contributes to increased 
intracellular survival of this organism. A significant TH1 response observed after 
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intranasal inoculation with B. bronchiseptica indicates that, there may be relevant 
intracellular phases of this bacterium during the infection cycle [64]. Chhatwal et al. 
suggested that, the expression of a temperature regulated acid phosphatase in B. 
bronchiseptica played a role in intracellular survival [25]. Forde et al. characterized the 
uptake and persistence of B. bronchiseptica in murine phagocytes using a 
bioluminescence-based reporter system [51]. In this study, B. bronchiseptica was 
mutagenized with a suicide vector carrying lux genes from Photorhabdus luminescens on 
a mini-Tn 5 derivative [51]. B. bronchiseptica was internalized by professional 
phagocytes in a dose-dependent manner and the bacterium survived intracelluarly for 
four days when a critical population size (>500:1 multiplicity of infection) was present 
[51]. This study also suggested that B. bronchiseptica may have an intracellular phase 
during the infection cycle.  
Diseases caused by B. bronchiseptica 
      B. bronchiseptica had been considered a respiratory pathogen of mammals since its 
identification in 1910 [60]. The involvement of this organism has long been recognized in 
diseases such as acute infectious tracheobronchitis in dogs, atrophic rhinitis in swine, and 
respiratory infections of laboratory animals [60]. These diseases are mostly self- limiting, 
but can be chronic and some times complicated by secondary invaders [6, 7, 60]. The 
hallmark of infection by this organism is prolonged, efficient colonization of ciliated 
epithelium of the respiratory tract [9].  The ability to interfere with ciliary function is an 
important factor in pathogenesis of B. bronchiseptica infections [9]. 
      Canine infectious tracheobronchitis, or kennel cough, is a highly contagious 
respiratory tract disease, affecting dogs, that is characterized by acute onset of cough [6, 
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7, 8, 9, 188]. Studies on experimental and natural infections of B. bronchiseptica in 
canines proved that this organism could be considered as a primary etiological agent in 
infectious tracheobronchitis [8]. The infection leads to moist, hacking, productive cough 
[7, 8, 9, 188]. Microscopic lesions were limited to the ciliated epithelial mucosa with 
influx of polymorphonuclear cells being a prominent feature [9]. Bacterial colonization in 
experimental studies reaches its maximum at seven days after aerosol exposure and slow 
progressive clearance occurs thereafter [8]. Many infected animals can remain 
asymptomatic and the disease is usually self- limiting [9, 33]. 
      Atrophic rhinitis is an upper respiratory tract disease of pigs characterized by 
degeneration and atrophy of nasal turbinate bones leading to visible distortion, and 
shortening of the snout [60, 169]. B. bronchiseptica can cause moderately severe 
reversible turbinate atrophy [48, 49, 162]. Dermonecrotic toxin production by B. 
bronchiseptica is correlated with turbinate atrophy [113,162, 165]. Experimental 
infections in gnotobiotic pigs implicated that the colonization with phase I cytotoxic 
strains of B. bronchiseptica damages the nasal mucosa and predisposes to colonization 
by toxigenic P. multocida that can lead to a more severe form of the disease [162, 165]. 
Two recent studies on co- infection with B. bronchiseptica and porcine reproductive and 
respiratory syndrome virus (PRRS) strengthen the hypothesis that, B . bronchiseptica 
infection can adversely affect the respiratory tract defense mechanism leaving animals 
vulnerable to infection with secondary agents like P. multocida [15, 16].  
      There has been increased documentation of B. bronchiseptica respiratory tract 
infections of cats [181]. Clinical and experimental studies have proved that B. 
bronchiseptica can also be a primary respiratory pathogen in cats [84]. Laboratory 
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animals, especially guinea pigs, rabbits and rats get respiratory tract infections with B. 
bronchiseptica [60]. Infections can be insidious in such populations; seventy five 
percent of the rabbits in a commercial rabbitry were infected naturally with B. 
bronchiseptica without showing any disease [35]. B. bronchiseptica has also been 
associated with respiratory tract infections in horses [26, 76 ]. Rats and mice have been 
used as experimental animal models to study B. bronchiseptica pathogenesis [32, 33, 72, 
117]. Intranasal infection with a subletha l dose of B. bronchiseptica leads to prolonged 
asymptomatic colonization in mice and rats [117].     
      There are well-documented cases of B. bronchiseptica infection in human beings 
[204]. They are usually associated with immunocompromised patients.  In an extensive 
review, Woolfrey and Moody concluded that the agents might be occasionally 
encountered as a commensal of the respiratory tract and rarely as a pathogen in severely 
immunocompromised patients [204]. Animal contact may or not be a recognizable risk 
factor and nosocomial human to human transmission has been reported [176]. Infections 
in immunocompetent children are also reported [177] 
Immunity to B. bronchiseptica infections 
      Most naturally occurring B. bronchiseptica infections are localized to the respiratory 
tract [6, 60]. Recovery from infection in dogs resulted in resistance to re- infection that 
lasted for 6 months [6, 60]. Vaccination with formalin killed bacteria produced high titers 
of serum agglutinins but did not prevent infection [7]. The dogs that recovered from 
experimental infection and were maintained in isolation were resistant to a subsequent 
aerosol challenge seven months after recovery. B. bronchiseptica specific sIgA in the 
respiratory tract has been correlated with protection [11]. Killed, parenterally, inoculated 
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whole-cell vaccines of B. bronchiseptica were successfully used to prevent death, 
bronchopneumonia and carrier state in lab animals [60] and to protect swine from B. 
bronchiseptica induced-atrophic rhinitis [60, 102]. A subcellular B. bronchiseptica 
vaccine containing concentrated cell wall fractions provided greater protection in swine 
than the whole cell vaccines [60]. A local immune response to Bordetella infection was 
achieved by a live, avirulent intranasal vaccine, which induced early protection against 
disease in swine and dogs. Intranasal immunization with live avirulent bacteria may 
reduce clinical disease and duration of shedding and may induce some degree of 
colonization resistance [7, 60]. Although some parenteral vaccines induced high levels of 
agglutinating antibodies, they did not provide protection from diseases [60]. An acellular 
extracted antigen vaccine protected dogs from disease and reduced shedding of B. 
bronchiseptica [41]. In dogs, parenteral or intranasal B. bronchiseptica vaccines may 
provide substantial protection from clinical signs of respiratory tract diseases, 
administration of both types of vaccines, in sequence, provided greatest degree of 
protection against the disease [41].  
      Gueirard et al. noted that colonization of lungs in BALB/c mice inoculated with a 
live, virulent strain of B. bronchiseptica, increased during the first 10 days and decreased 
thereafter [64]. A non-virulent strain in similarly inoculated mice, was cleared from lungs 
by 6 days. In this study, a human isolate lacking adenylate cyclase was unable to induce 
progressive infection of the respiratory tract of mice.  Infection was also associated with 
an influx of leukocytes into the respiratory tract. B. bronchiseptica-reactive serum IgG 
and IgM were observed soon after infection, levels gradually increased for 14 days and 
remained constant for 117 days. Much of the IgM production that was produced was not 
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specific for B. bronchiseptica [64] perhaps due to triggering mechanisms unrelated to 
specific epitope recognition. B. bronchiseptica specific IgA in serum was induced soon 
after infection (14 days post-infection) and increased during the 117 days observation 
period. A cellular immune response was demonstrated to B. bronchiseptica and adenylate 
cyclase. High levels of IFNg and IL 1-a detected in antigen- induced proliferation assays 
indicated that a Th1 type of immune response was produced during B. bronchiseptica 
infections. B. bronchiseptica infections were not accompanied by immunosuppression of 
cellular response to mitogens [64]. 
      Mattoo et al. established a correlation between presence of fimbriae and effective 
tracheal colonization of B. bronchiseptica in mice and rats [117].  They demonstrated that 
the majority of serum IgM generated following B. bronchiseptica infection in rats was 
against fimbriae [117] and suggested that fimbriae might be involved in modulation of 
the humoral immune response [117]. Neither serum nor mucosal IgA response was 
detected in rats infected with B. bronchiseptica. It was postulated that absence of an IgA 
response might have been due to antagonistic effect of toxins produced by the type III 
secretion system [117]. This suggestion was supported by another study in which, mice 
infected with type III secretion mutants, had higher titers of anti-bordetella antibodies 
than mice infected with wild-type organisms [207]. 
Heterologous antigen expression in Bordetella spp. 
      Although there are several studies on expression of Bordetella antigens in E. coli, 
very little is known about heterologous antigen expression in Bordetella species. Suarez 
et al. expressed pertussis toxin gene from B. pertussis in B. bronchiseptica [185]. Since 
pertussis toxin is an essential component of acellular vaccines against whooping cough, 
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the aim of their study was to overcome the problems associated with slow growth and 
poor yields of pertussis toxin in B. pertussis, to facilitate improved industrial production, 
and to avoid bio-safety concerns of handling a human pathogen like B. pertussis. They 
constructed a chromosomal integrate of the pertussis toxin operon in B. bronchiseptica, 
that would allow inducible production of pertussis toxin from a promoter responsive to an 
aromatic inducer.  
      The first study on expression of a foreign protective antigen in Bordetella spp was 
published by Renauld-Mongenie in 1996 [161].  This study explored the possibility of 
using B. pertussis as a live mucosal vaccine vector for a protective antigen of 
Schistosoma mansoni. A S. mansoni, glutathione S-transferase gene was fused to the 
filamentous haemagglutinin gene of B. pertussis and the corresponding protein was 
expressed on the cell surface of B. pertussis. A single intranasal inoculation of the 
recombinant strain induced mucosal antibody to Schistosoma antigen (Sm28GST). This 
was the first study to demonstrate the utility of recombinant respiratory pathogens for the 
delivery of heterologous protective antigens. Later, in 1998, the same group of scientists 
created an attenuated derivative of B. pertussis and showed that attenuation of pertussis 
toxin resulted in an improved immune response to filamentous haemagglutinin and 
Sm28GST [128, 129]. A single intranasal inoculation of this strain induced protection 
against the parasite and protection against B. pertussis in mice. The ability of pertussis 
toxin-deficient and wild-type Bordetella to induce antibody response at a distal mucosal 
site was examined by Mielcarek et al. [128]. They observed that intranasal infection with 
B. pertussis produced detectable antibodies in the genital tract. Although pertussis toxin 
has been reported to have adjuvant properties, this study did not find any 
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immunomodulating effect of pertussis toxin in inducing local antibody response [128]. 
Administration of purified FHA by the intranasal or intravagina l route could boost the 
immune response generated at these sites. In another study by Mielcarek et al., priming 
with recombinant B. pertussis expressing Sm28GST and subsequent intranasal boosting 
with the foreign protein (Sm28GST) induced a systemic antibody response against the 
foreign antigen [130].  
      The bioluminescence gene from P. luminescence has been expressed in B. 
bronchiseptica and used to study the uptake and persistence of B. bronchiseptica in 
murine phagocytes [51]. A mini-Tn-5 promoter probe carrying the intact lux operon from 
P. luminescence was introduced into B. bronchiseptica and was used to create a pool of 
bioluminescent fusion strains of B. bronchiseptica. This allowed measurement of light 
output from the recombinant organisms without the addition of exogenous substrate.  
      Purified recombinant, detoxified adenylate cyclase of B. pertussis has also been used 
to deliver multiple epitopes from lymphocytic choriomenigitis virus and human 
immunodeficiency virus to induce a cytotoxic T cell-mediated immune response in mice 
[44]. The cell invasiveness and availability of permissible insertion sites are features of 
adenylate cyclase that may be useful for induction of protective cell-mediated immune 
responses against pathogens [44]. 
Advantages of mucosal immunization 
      The mucosal surfaces of the gastrointestinal, respiratory, and urogenital tracts 
represent the major port of entry for several human and animal pathogens [118, 119]. 
Mucosal exposure to foreign antigens during infection often results in development of an 
immune response. Therefore, mucosal immunization with specific vaccine antigens may 
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be more effective for immunization against infections acquired through mucosal surfaces 
[118, 119]. Mucosal immunizations offer several advantages compared to parenteral 
immunizations [24, 118, 119, 143]. They can induce mucosal as well as systemic immune 
responses and because of reduced direct contact with vaccine components in the systemic 
circulation can increase vaccine safety [24, 143]. Easy administration of multiple 
vaccines and reduced requirement for trained personnel make mucosal immunization 
strategies attractive [24, 143].  
Mucosal immune system 
      There are many non-specific defense mechanisms that play important roles at 
mucosal surface. Mucus, acid, enzymes, bile, lysozyme, and lactoferrin secreted at the 
mucosal surface can inhibit microbes [118, 119]. Peristaltic contraction of smooth 
muscles, ciliary action of the epithelium, and tight junctions of the mucosal epithelium 
can exclude microorganisms from the mucosal surfaces and prevent invasion into deeper 
body tissues [103, 105, 118, 119]. Mucosal surfaces of gastrointestinal, respiratory and 
urogenital tracts are covered by a single layer of epithelial cells, which face an 
environment rich in pathogens. Some pathogens have developed effective mechanisms to 
colonize and invade these surfaces and, in defense, mucosal tissues are heavily populated 
with cells of the immune system [80, 103, 105, 118, 119]. The specialized sites where the 
induction of mucosal immunity begins consists of organized mucosa-associated lymphoid 
tissue called O-MALT and wide spread diffused mucosa-associated lymphoid tissue 
called D-MALT [103, 105, 118, 119]. O- MALT occurs in tonsils, respiratory tract and in 
gastrointestinal tract [103, 105, 118, 119]. Dendritic cells or specialized epithelial M cells 
capture and sample antigens at the mucosal surface [103, 105, 118, 119]. Antigen 
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sampling across the stratified epithelia of the oral cavity, vagina, and epithelium of the 
upper airways is carried out by migratory dendritic cells, which carry antigens to local O-
MALT or to distal lymphoid tissue. Antigen sampling across the intestinal and bronchial 
epithelia is carried out by M-cells that deliver antigen to local O-MALT [103, 140]. In 
the airway epithelium, dendritic cells form a network with up to 700 dendritic cells /mm2 
[103, 105, 118, 119]. They represent major histocomatibility complex class II bearing, 
antigen-presenting cells of the airways and constitute the first line of defense against 
inhaled antigens. In the bronchi and in the gastrointestinal tract, M cells transport 
macromolecules, particles and microorganisms to the mucosal lymphoid follicles and 
initiate a secretory immune response [103, 105, 118, 119]. Although uptake and sampling 
of microorganisms by M cells lead to an immune response and eliminate mucosal 
infections, some viruses and bacteria exploit M cells for gaining entry into the host [103, 
105, 118, 119].  
      Both humoral and cellular immune responses are generated at mucosal surfaces [103, 
105, 118, 119]. IgA is the major antibody seen at mucosal surfaces [105]. The surface 
area occupied by mucosal epithelium in the body is enormous due to many macroscopic 
and microscopic foldings; as a result it may not be too surprising that IgA is estimated to 
be the most abundant immunoglobulin class found in the body (>50mg/kg 
bodyweight)[105]. IgA blocks the attachment of infectious agents to mucosal epithelia 
and provides an immune exclusion barrier in secretions against microbial pathogens, 
toxins, and other antigens [105, 139]. IgA can bind to lectin- like bacterial adhesins 
through its carbohydrate moieties and may, in this fashion, also block bacterial adhesion 
to receptors on epithelial cells. IgA also neutralizes viruses within the epithelial cells, 
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excretes antigens from sub-epithelial compartments across the epithelium into secretions, 
and activates complement through the alternate pathway [105]. 
      IgA is secreted from plasma cells as dimers that bind to polymeric immunoglobulin 
receptors (pIgR) on the basolateral surface of epithelial cells that line the mucous 
membrane [105]. At the apical surface, proteolytic cleavage splits the external domain of 
pIGR (secretory component) and releases the dimeric IgA-secretory component complex 
(secretory IgA) into the mucosal secretions. In the secretions, IgA binds to antigens and 
prevent them from attaching to or penetrating the mucosal surfaces [105, 139, 140]. 
      Like IgA, pentameric IgM also plays a role in preventing mucosal infections. IgM 
binds to the pIgR with less affinity than IgA [105]. IgG, the principle class of systemic 
antibody, is also seen in mucosal secretions and may enter the mucosal surface through 
diffusion. IgE also is considered to be a significant mucosal immunoglobulin [105]. 
Antibodies passively administered or actively induced at mucosal surfaces can protect 
mucosal surfaces from infection and invasion of pathogens. The success of oral 
vaccination for poliomyelitis and the abundant knowledge about mucosal immunity has 
created great interest in mucosal vaccination against infections that gain entry through the 
mucosal surfaces [105, 118]. 
      Protein antigens applied to a mucosal surface can stimulate a mucosal immune 
response with secretory IgA production, a systemic immune response with IgG or IgM or 
development of mucosal tolerance with systemic unresponsiveness [103, 105, 143]. 
Tolerance is defined as loss of systemic immune responsiveness to that antigen following 
mucosal exposure [143]. Tolerance may be due to direct inactivation of antigen-
sensitized lymphocytes via clonal deletion or anergy [143]. Other factors such as 
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interaction between regulatory and effector T cells, Th1 versus Th2 and g/d T cell 
receptors, bystander suppression, and tolerogenic proteins may also be involved in the 
induction of tolerance [143]. 
Vaccination strategies to induce mucosal immune response 
      Mucosal surfaces of the body are colonized with commensal bacteria, which may not 
cause any harmful effect to the host, and the maintenance of this microflora is based on a 
balanced immune response, which avoids an excessive overgrowth [78]. Even in 
individuals that are fully immunocompetent, bacterial infections of the gastrointestinal, 
respiratory and urogenital mucosa are among the leading problems in man and animals 
[78]. Parenteral vaccines are generally not very effective for inducing an immune 
response that prevents mucosal infections and they do not induce immune responses at 
mucosal sites [78]. They are usually active against invasive systemic diseases [205]. As 
already mentioned, stimulation of one mucosal site can lead to immune responses at 
distal mucosal sites [205].   
      Stimulation of a mucosal immune response requires efficient delivery of vaccine 
antigens to mucosal inductive sites. Often, enhancement of the immune response requires  
co-administration of adjuvants [24]. In development of vaccines against mucosal 
infections, it is important to define the nature of immune response that is required for 
protection [118, 119].  
      Oral delivery of vaccines has been most widely studied because of the convenience of 
vaccination through this route [173, 174]. Intranasal immunization will be advantageous 
for the control of pathogens whose route of entry is the respiratory tract because the 
magnitude of immune response produced will be maximum at this site [205]. Intranasal 
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delivery of vaccines is more effective in inducing systemic and mucosal immune 
response compared to other routes [205]. Mucosal immunizations with live organisms 
that colonize the nasal cavity may induce strong, long lasting immunity after a single 
inoculation [205]. Compared to oral vaccination, intranasal vaccination may have the 
advantages of lower dose requirement, greater stability, and less competition from 
colonizers [205]. Antigen will be taken up by the antigen presenting cells at the nasal 
mucosa (mainly dendritic cells) and will be presented to underlying nasal associated 
lymphoid tissue (NALT), where they induce a secretory IgA response [205], or the 
trapped antigen will be carried to local draining lymph node to initiate a systemic IgG 
response [105, 118, 205]. Recirculation and homing of memory immune cells through a 
common mucosal system can induce antibody response at distant mucosal sites [205]. For 
example, intranasal immunization with B. pertussis resulted in an antibody response at 
the genital surface [129]. Compartmentalization of the common mucosal immune system 
establishes a theoretic base for considering the best route to deliver mucosal vaccine 
[205]. 
      Delivery of antigens by the mucosal route is associated with major problems like poor 
immunogenicity and susceptibility to degradation [123]. To overcome these problems, 
strategies such as entrapment into biodegradable microspheres, liposomes, their 
production by attenuated viral/ bacterial carriers or transgenic plants, or their 
administration with mucosal adjuvants are being used [123]. 
      A number of adjuvants enhance the immunogenicity of antigens when delivered by 
parenteral route. Only a few molecules such as cholera toxin produced by Vibrio cholerae 
and heat labile toxin produced by Escherichia coli have been reported to act as mucosal 
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adjuvants [39, 79]. The potential side effects of these toxins limit their use in vaccinations 
[180]. Co-administration of cytokines and bacterial DNA containing unmethylated CpG 
dinucleotide motifs have been shown to be effective as vaccine adjuvants [100, 123]. 
Non-living Antigen delivery systems  
      Controlled delivery systems of microparticles consisting of polyesters, polylactides 
and glycolides are primary candidates for development of microencapsulated vaccines 
[123, 127]. Vaccine antigens are incorporated either adsorbed or chemically bound to the 
matrix [123, 127]. Incorporation of antigens into such microparticles protects the antigens 
from degradation and facilitates uptake of antigen and antigen presentation that leads to 
more efficient systemic and mucosal immune responses [123, 127]. The most important 
limitations of using vaccine antigens in microparticles are: stability of the antigens, the 
particle uptake, technical difficulties in delivery and associated toxicological issues [123, 
127]. Liposomes are lipid vesicles formed when phospholipids are exposed to an aqueous 
environment and can act as immunoadjuvants, protect antigens, and are considered safe 
immunoadjuvants [123, 127]. Immunostimulating complexes (ISCOMS) are complexes 
built up by cholesterol, lipid, immunogen, and saponin. Administration of ISCOMS 
through parentral or mucosal routes can induce antigen specific immune responses [123, 
127]. 
Live viral vectors 
      The natural ability of the viruses to infect target cells via specific entry mechanisms 
can be utilized to deliver antigens to specific cell types for antigen presentation and 
immunization [69]. The two types of basic live viral vectors used are attenuated viruses 
and replication defective or host range restricted viruses [69]. Several viruses such as 
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poxviruses and adenoviruses have served as vectors to deliver heterologous antigens. 
Vaccinia virus is the most studied viral vaccine vector [69]. Attenuated strains of 
Vaccinia virus expressing rabies virus glycoprotein have been used in field 
immunizations to protect wild animals from rabies [69]. Administration of these vectors 
to wild animal populations via polyurethane baits led to development of high neutralizing 
antibody titers against rabies virus [69]. Another commercially licensed virus vaccine 
vector in United States is fowl poxvirus that expresses glycoproteins of Newcastle 
disease virus. This vector can protect poultry from fowl pox and Newcastle disease [69]. 
      Adenovirus vectors that can be administered orally are receiving attention. A number 
of antigens such as vesicular stomatitis virus glycoprotein, hepatitis B virus surface 
antigens, herpes simplex surface antigens have been successfully expressed in adenovirus 
vectors [69]. Herpes simplex virus, varicella zoster virus, poliovirus, simian 
immunodeficiency virus are the other viral vectors under study [69]. Replication 
defective mutants of poxvirus, adenovirus, and herpes simplex virus are now available 
and are considered to be good vaccine vector candidates because of their increased safety 
over wild-type and attenuated vaccine vectors [69]  
Live bacterial vectors  
      Live multivalent vaccines using attenuated recombinant bacterial vectors have several 
advantages. Many proposed live vectors are administered by the oral or respiratory routes 
[124, 173, 174]. They are inexpensive to manufacture and, the live nature of the delivery 
system and the danger signals provided might make weak tolerogenic antigens more 
immunogenic [124, 173, 174]. Depending on the type of pathogenic mechanisms 
employed by a live bacterial vaccine vector, an immune response could be generated 
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through TH1 or TH2 pathways [124]. The specificity of different vectors to colonize 
different mucosal surfaces can be utilized to target an immune response at desired sites. 
Live antigens that express foreign protective antigens in host tissues may result in longer 
antigen presentation than non- living or parenterally administered preparations. Live 
attenuated bacterial vectors expressing heterologous protective antigens hold several 
attractive features compared to contemporary vaccines [124, 173, 175]. They are; 
1) Unlimited cloning capacity 
2) Effectiveness after single-dose vaccination  
3) No requirement for addition of adjuvant  
4) Non-invasive and easy administration procedure  
5) Potential for producing multivalent vaccines 
6) Low reactogenicity and low cost of production.  
      Additionally, antibiotic susceptibility allows an extra measure of safety to bacterial     
vectors, which is an advantage over live viral vectors [124, 173, 174, 203]. Both 
attenuated and commensal organisms have been successfully used as live vaccine 
vectors and some of them are discussed below. 
      Salmonella are intracellular pathogens involved in many important diseases of 
humans and animals. Following ingestion, salmonellae replicate in peyer's patches and 
disseminate via the MALT to the systemic tissues. Such infection will lead to either 
disease or broad-based immune responses that include systemic, mucosal, humoral and 
cell-mediated immunity [173, 174]. Mutants deficient in synthetic pathways involved in 
aromatic amino acid, purine, adenylate cyclase, and PhoP/PhoQ systems are well 
characterized and are efficient carriers for antigens [173, 174]. A vast number of 
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heterologous antigens have been expressed in attenuated salmonella including, bacterial, 
viral and parasitic antigens, eukaryotic proteins and cytokines [43, 173, 174]. Functional 
immune responses to these heterologous antigens have been demonstrated. 
Chromosomal integration of the genes encoding an antigen leads to stable, low level 
expression of the antigen. Plasmid mediated expression leads to high level expression 
but can result in instability of the plasmid and toxicity to the bacterial host [43, 173, 
174]. Nakayama et al. introduced balanced lethal vector systems in salmonella that were 
characterized by the maintenance of multiple copies without the requirement of 
antibiotic selection [53, 54, 186]. In these systems, a plasmid that carries a vital 
metabolic gene which is deleted in the host bacterial strain will lead to positive selection 
of the plasmid bearing strain. Genes for heterologous antigens can be incorporated on 
the rescue plasmid. In addition, sub-cellular location [167], gene transcription, and 
timing of expression in eukaryotic cells [77] may influence immunogenicity of the 
antigen. Rapid advances in understanding of the molecular basis of pathogenesis of 
salmonella species have resulted in development of several candidate vaccine vector 
strains [23, 173, 174]. Recombinant Salmonella typhimurium strains evoked local as 
well as systemic immune response to heterologous antigens by oral, nasal, rectal and 
vaginal routes of immunization [82].  
      BCG (Bacillus Calmette Guerin), an avirulent derivative of Mycobacterium bovis, is 
widely used as a vaccine against tuberculosis in human beings [144]. While the slow 
growth rate of Mycobacterium species has impeded research, there have been 
tremendous developments like the discovery of shuttle plasmids (plasmids that can 
replicate in Mycobacterium and E. coli), gene replacement technology based on 
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homologous recombination with M. smegmatis, and antigen secretion systems [144]. 
Augmentation of immune responses by the well-known adjuvant activity of BCG is also 
an advantage. BCG has been engineered to express a variety of heterologous antigens. 
They include proteins from human immunodeficiency virus, tetanus toxin, 
pneumococcal surface protein, pertussis toxin and parasite antigens like schistosoma, 
leishmania, or plasmodium antigens [144]. BCG that secretes immunostimulatory 
cytokines have been made and tested as anti-tumor agents [144]. Since a large 
proportion of human beings are already immunized with BCG, the use of BCG that 
expresses heterologous protective antigens for control of tuberculosis and other common 
diseases may be realized soon. 
      Vibrio cholerae is a Gram-negative organism responsible for the disease, cholera. 
This is a non- invasive organism that induces potent long- lasting mucosal and systemic 
immune responses [69, 171]. The ability of this organism to adhere to the M cells has 
been utilized for vaccine antigen delivery to the gastrointestinal tract [69]. Attenuated 
strains that lack cholera toxin have been used to induce mucosal and systemic antibody 
responses to heterologous antigens [69, 171].  
      B. pertussis has been studied as a mucosal vaccine vector directed to the respiratory 
tract. The glutathione transferase gene from Schistosoma mansoni was integrated into the 
filamentous hemagglutinin gene of B. pertussis and was expressed [161]. A single 
intranasal immunization with the recombinant B. pertussis lead to immune responses to 
the Schistosoma antigen as well as to B. pertussis [161]. Brucella spp have also been 
considered as possible vectors for intracellular delivery of antigens [28]. 
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      Mucosal inoculation with recombinant Gram-positive bacteria such as Streptococcus 
gordonii and certain strains of Lactobacillus, which are among the endogenous 
microflora, have also been used to deliver heterologous antigens [155, 168]. 
Streptococcus gordonii, originally isolated from the oral cavity of humans, is capable of 
colonizing the oral cavity and vagina of mice. A number of antigens have been expressed 
in S. gordonii by replacing the sequences encoding the surface exposed domains of the 
M6 protein with foreign genes of interest [155] The secretion signal and cell wall 
anchoring domain of the M6 protein served to direct the export of the antigen to the 
surface. The foreign proteins expressed in S. gordonii were integrated into the 
chromosome by homologous recombination so that genes were stably maintained in the 
chromosome in vivo without any antibiotic selection.  
      Nonpathogenic staphylococcal species such as S. xylosus, and S. carnosus, which are 
widely used in meat fermentation processes, have been developed as live bacterial 
vectors [175]. High copy number shuttle vectors were advantageous in that they 
provided multiple copies of the foreign gene per cell. In these systems, the promoter, 
signal sequence and propeptide sequence from the S. hyicus lipase gene were utilized to 
achieve translocation through the cell membrane. However, large number of 
immunizations and surface display of heterologous antigens were necessary for 
induction of an immune response [175]. 
      Lactococcus lactis a Gram-positive bacterium used in industry is non- invasive, non-
pathogenic and does not colonize the mucosal surface. Researchers have exploited the 
microparticle nature of this bacterium in heterologous antigen delivery [19]. Several 
antigens have been expressed in Lactococcus using an inducible T7 RNA polymerase 
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system or the pTREX series of constitutive expression plasmid. When applied via a 
mucosal route, mucosal as well as systemic immune responses were noticed in mice. 
      Lactobacillus, a Gram-positive bacterium that is prominent in human indigenous 
gastrointestinal flora, has been used to express heterologous antigens from plasmid 
vectors and following chromosomal integration [168]. The potential for induction of 
immunological tolerance to foreign antigens has to be considered when utilizing 
commensal bacteria as vaccine delivery vehicles. At present, the relationship between 
normal flora and the host immune system is very unclear [168]. Listeria monocytogenes, 
a facultative intracellular Gram-positive pathogen, is a promising vaccine carrier for 
evoking a cellular immunity [65] 
      There are potential problems associated with the use of live bacterial vectors. 
Reversion to virulence is one of the major concerns associated with live bacterial vectors.  
Stability of attenuated phenotypes should be ensured by careful inactivation of target 
genes; single gene inactivation is less desirable [18, 53, 124]. Due to preexisting 
immunity, the vaccine dose required to trigger immune responses in endemic areas and 
nonendemic areas may differ. Medina et al. suggested that presentation of the vaccine in 
different formulations according to geographic area might solve this problem [53, 124]. 
The use of plasmids for expression of foreign genes may lead to plasmid instability and 
loss of antigen expression [18, 53, 124]. The presence of additional genes such as 
antibiotic markers used for positive selection is not desirable [124]. The use of low copy 
number plasmid vectors containing killing systems, partition function and non-antibiotic 
selection markers are advisable. Integration of a foreign gene into the chromosome of the 
host strain may lead to low level expression from a single copy gene and be insufficient 
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to generate an effective immune response [18, 53, 124]. Another strategy, which may be 
effective, is the use of in-vivo activated promoters [124]. The expression of particular 
vaccine antigens by non-pathogenic commensal or environmental organism may enhance 
their virulence in human or animal populations, and increase the environmental risk. 
Also, horizontal gene transfer from vaccine strains to mucosal flora or environmental 
organisms may pose a threat [124]. This can be prevented by incorporating conditional 
lethal systems [38, 136]. Prior exposure to the antigen carrier can compromise the 
efficacy of a vaccine candidate. As reported in salmonella, [3] utilization of different 
carrier strains or bacterial serotypes for preparation of vaccines or allowing an established 
optimal window for readministration of vaccine may eliminate this risk [124]. Host 
genetic factors may also modulate the type of immune response [124]. Diversity in MHC 
genes, and presence or absence of some genes associated with immune system can lead to 
differences in the type of immune responses generated [124]. It is also important to have 
proper balance between attenuation and immunogenicity. The dissemination of live 
attenuated microorganisms in the field may pose a risk of disease, especially in 
immunocompromised individuals and require stricter safety guidelines [69]. Vectors that 
are highly susceptible to antimicrobial agents are most desirable.  
Conclusion 
      Vaccination constitutes the most cost effective tool for the prophylaxis of infectious 
diseases. Most pathogens gain entry into the body through the mucosal surfaces. So 
administration of immunogens through the mucosal route and induction of immune 
responses at these sites are essential. Delivery of vaccine antigens by bacterial carriers 
has resulted in effective humoral and cell mediated immune responses. The potential 
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value of live bacterial vectors for vaccination purposes was recognized by the World 
Health Organization (190). B. bronchiseptica, effectively colonizes the respiratory tract 
of mammals, and is an ideal candidate as a mucosal vaccine vector. Application of this 
system in the disease, atrophic rhinitis, is a rational approach to refining existing vaccines 
and could be expanded to control other diseases in animals. 
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Abstract 
       Bordetella bronchiseptica, an adept colonizer of the upper respiratory tracts  
of mammals, may be selectively utilized as a live bacterial vector to deliver protective 
antigens to the respiratory tract. Promoters and conditions for optimal expression of 
foreign antigens in B. bronchiseptica have not been determined. In this study, a B. 
bronchiseptica promoter region (P9) related to heat shock protein genes was identified 
using a green fluorescent protein (GFP) reporter system. The region identified has 98% 
homology to the cpn10/60 gene of Bordetella pertussis. The efficiency of this promoter 
to drive GFP expression was analyzed and compared in four B. bronchiseptica strains 
using flow cytometry. GFP expression from the P9 promoter was also compared to that 
of a B. bronchiseptica fimbrial gene (fim N) promoter and Escherichia coli derived tac 
promoter. The P9 promoter had the highest level of activity in all B. bronchiseptica 
strains tested under normal laboratory incubation conditions using common media. The 
tac promoter was more active in E. coli than in B. bronchiseptica. The fim N promoter 
had low level activity, detectable only in bvg positive strains of Bordetella 
bronchiseptica. The P9 promoter may be a good candidate for expression of 
heterologous antigens in this species. In addition, B. bronchiseptica constructs with 
strong constitutive expression of GFP may be useful to characterize the adherence and 
colonization of this bacterium. 
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Introduction 
      Bordetella bronchiseptica is a respiratory pathogen, which infects a wide variety of 
host species including domestic, laboratory and wild animals and may opportunistically 
infect humans [4, 14]. B. bronchiseptica can express a battery of adhesins, like fimbriae, 
filamentous haemagglutinin, adenylate cyclase and pertactin that enable it to colonize the 
upper respiratory tract of various host species [10]. The ability of this organism to 
efficiently colonize the respiratory tract may be utilized to deliver protective antigens 
from other pathogens to the respiratory tract. Intranasal inoculation with B. 
bronchiseptica has been shown to induce long lasting humoral and cellular antibody 
responses in mice [15]. Mucosal application of vaccines induces immune responses at 
systemic and mucosal sites [24, 28]. A single intranasal inoculation of mice with B. 
pertussis expressing a Schistosoma antigen was able to induce mucosal antibody 
responses in the respiratory tract as well as at other mucosal sites [25, 26, 32]. Compared 
to the oral route of immunization, intranasal vaccine application may have the advantage 
of low dose requirement, greater stability and less competition from colonizers [42]. Live 
bacterial vectors, which can colonize the respiratory tract, are attractive candidates for 
this purpose [28]. 
      Many virulence genes in the genus Bordetella are controlled by a two-component 
signal transduction system encoded by the bvg locus. The proteins produced by this 
locus, BvgA and BvgS, are responsible for phenotypic modulation in response to 
environmental signals like temperature and certain chemicals [10] and, the promoter 
region of this operon contains a cytosine repeat region that is subject to frequent 
mutations [3]. The significance of the bvg locus in infection and the effect of in vivo 
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conditions on its expression are not completely understood. Therefore, to study 
heterologous antigen expression, a strong promoter was sought that could drive 
constitutive expression of genes in B. bronchiseptica 
      In this study, a B. bronchiseptica promoter region (P9) related to heat shock protein 
genes was identified utilizing a promoter-probe vector carrying a promoter- less green 
fluorescent protein gene. This promoter induced high level expression of GFP in four 
different strains of B. bronchiseptica and was compared to GFP expression from the 
Escherichia coli derived tac promoter and a bvg regulated fim N gene promoter [17] 
under common laboratory conditions. B. bronchiseptica expressing GFP from P9 
promoter was utilized to study in vitro adherence to Vero cells and colonization of mouse 
respiratory tract. 
Materials and methods 
Plasmids, bacterial strains, and enzymes  
      The origin of B. bronchiseptica strains has been previously described [6]. Strain 55 is 
a live attenuated B. bronchiseptica (ATCC 31437) vaccine strain. The INVF', (Invitrogen 
Inc., San Diego, CA) is a lac represser gene deficient Escherichia coli strain. All bacteria 
were grown in Luria Bertani (LB) agar or broth with appropriate antibiotic selection at 
37oC unless otherwise indicated. Restriction enzymes and Taq polymerase were products 
of PANVERA, Madison, WI. Wizard plus SV miniprep kit (Promega, Madison, WI) was 
used for plasmid isolation.  The plasmid, pBBR1MCS2, (kindly provided by Michael E. 
Kovach) was used for all cloning purposes [20]. The plasmid pBBR1-KGFP (kindly 
provided by Stephan Kohler) was used to obtain the gfpmut3 gene [9, 19]. 
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DNA manipulation 
      All polymerase chain reactions were performed in a Gene Amp PCR system 9600 
(Perkin Elmer, Narcross, GA).  A 30-cycle program consisted of denaturing at 95oC for 
1.5 minutes, annealing at 50oC for 30 seconds, and extension at 72oC followed by a last 
cycle of 5 min extension at 72oC. All primers used for PCR amplification were designed 
to contain restriction enzyme sites (underlined). 
      Promoterless gfpmut3 gene was amplified from pBBR1-KGFP by PCR using forward 
primer 5'-CGGGATCCGATGAGTAAAGGAGAAGAA-3'and reverse primer  
5'-CGGAATTCTTATTTGTACAATTCATCC-3' and cloned into the BamHI and EcoRI 
sites of pBBR1MCS2. The resulting plasmid was designated as pBBRGFP. 
Chromosomal DNA was isolated from B. bronchiseptica strain 110H using Easy DNA 
kit (Invitrogen Inc., San Diego, CA). It was digested with Sau3A1 and electrophoresed 
on an 8% agarose gel. DNA fragments ranging from 0.25-3kb were purified from agarose 
gel using Quiagen gel purification kit (Quiagen Inc., Valencia, CA) and ligated to BamHI 
digested, calf intestinal alkaline phosphatase (New England Biolabs., Beverly, MA) 
treated pBBRGFP. The ligation mixture was electroporated into B. bronchiseptica strain 
110NH (Bvg-, avirulent phase) using a CELL-PORATOR Electroporation System 
(GIBCO-BRL., Gaithersburg, MD) following the manufacturer’s instructions. This strain 
was used to avoid the selection of bvg-regulated promoters. The electroporants were 
isolated on LB agar containing kanamycin (100mg/ml). After 3 days of incubation at 
37oC, cell suspensions from individual colonies were examined with a fluorescence 
microscope (Nikon FLUOPHOT, Garden City, New York) equipped with blue 
wavelength (375-490 nm) excitation filter and a 510nm barrier filter. The tac promoter 
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was amplified from pGEX-5X-1 (GST gene fusion expression vector from Pharmacia 
Biotech. Piscataway, NJ), using forward primer 5'-GGTCTAGACTGCACGGTGCACC-
3' and reverse primer 5'-CGGGATCCTGTTTCCTGTGTGA-3' and cloned in to XbaI 
and BamHI sites of pBBRGFP. The resulting plasmid was designated as pBBRTACGFP. 
      To construct a plasmid expressing GFP under the control of fim N promoter, the GFP 
gene was amplified with the same forward primer used for constructing pBBRGFP and 
the reverse primer, 5'-CGGGATCCTTATTTGTACAATTCATCC-3' and cloned into a 
unique BamH I site in the fim N gene in PCR2-FIM (11). This construct was amplified by 
a primer specific to the 5' region of fim N (5'-
GGAAGCTTGCCATCACCAACTTATGTG-3') and the same GFP reverse primer used 
for cloning pBBRGFP and cloned into the Hind III and EcoR I sites of the pBBR1MCS2 
to obtain plasmid pBBRFIMGFP. All recombinant plasmids were electroporated into B. 
bronchiseptica strains 110H, 110NH, R5 and Strain 55. 
Growth curve  
      Bacterial growth curves were determined for each strain in LB broth, Brucella broth 
and Stainer Scholte broth (SS broth) [35]. Each medium (10ml) was inoculated with 
0.5ml of overnight culture of the B. bronchiseptica strains carrying recombinant plasmids 
at 1:20 dilutions and incubated at 37oC in a rotary shaker (220rpm). At selected time 
points 200ml of the culture was transferred to duplicate wells of 96-well microtiter plates. 
The plates were read at an optical density of 592nm on an ELX800 ELISA reader (BIO-
TEK instruments Inc., Winooski, VT). 
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Flow cytometric analysis 
      Bacteria containing the recombinant plasmids were grown in LB broth, Brucella broth 
or SS broth to late log phase at 37oC and 220 rpm. One ml of the culture was pelleted by 
centrifugation at 14,000 rpm for 1minute. The pellet was washed 2 times in phosphate 
buffered saline (PBS) and suspended in PBS to an approximate OD590 of 0.2. Bacterial 
suspensions were analyzed in a FACSVantage SE (Becton &Dickinson, San Jose, CA) 
equipped with argon laser exciting at 488nm and emitting at 540nm. Forward versus side 
light scatter was used to gate the bacteria and the data was collected using logarithmic 
amplifiers. A total of 10,000 events were acquired for each sample. The mean 
fluorescence intensity for each sample was determined by using CELLQUEST analysis 
software(Becton &Dickinson, San Jose, CA). B. bronchiseptica strains harboring plasmid 
pBBRGFP were used as negative controls. 
Adherence assays  
      Bacterial adherence to Vero cells was evaluated as previously described (17) with 
modifications. B. bronchiseptica strain 110H (Bvg + virulent phase) and 110NH ( Bvg- 
avirulent phase) were compared. Individual colonies from a 48 hr culture on LB agar 
were suspended in PBS to obtain an OD590 of 0.1 (2.5x10 8 CFU/ml). One ml of this 
suspension was mixed with a one ml suspension of Vero cells containing 1x10 6 cells/ml. 
This mixture was incubated for one hour at 37oC with gentle mixing. The suspension was 
centrifuged at 1000x g for 10 minutes to remove non-adherent bacteria. The resulting 
pellet was washed twice in Hanks Balanced Salt (HBS) solution and suspended in 1ml 
HBS. Adherence of recombinant B. bronchiseptica to Vero cells was measured by flow 
cytometric analysis as described above. 
 74 
 
In vivo plasmid stability 
      BALB/C mice (4-6 weeks old) were purchased from Harlan Laboratories 
(Indianapolis, IN) and were maintained by routine procedures in an AALAC accredited 
laboratory animal facility. Mice were inoculated with 50ml of bacterial suspension in 
PBS containing approximately 1x10 5 CFU of B. bronchiseptica 110H harboring 
PBBRP9GFP. Mice were anaesthetized with Isoflurane (Abbot Laboratories, North 
Chicago, IL) and 25ml of the bacterial suspension was instilled into each nostril. Mice 
were sacrificed at 3, 6, 12, and 24 hours after inoculation. The lungs and trachea were 
collected and fixed in 4% paraformaldehyde for 2hrs. The slow freezing protocol as 
described previously [34] was followed. Briefly, after fixation, the tissues were washed 
in PBS, embedded in Tissue-Tek O.C.T. (Miles Inc, Elkhart, IN) and stored at 4oC for 
24 hours. The tissues were transferred to a slow freezing container with isopropyl 
alcohol and allowed to freeze to -70oC. Sections were cut on a cryomicrotome 
(Minatome- Damon /IEC division, Needham Heights, MA), mounted in PBS and 
examined in a Leica SP2 laser scanning confocal microscope using 488nm argon laser 
line for excitation and a spectral setup for GFP to collect emission.  
 Results 
Identification and characterization of promoter 
      A library of clones containing fusions with the gfp gene and chromosomal DNA of 
B. bronchiseptica 110H was constructed.  A Bvg- avirulent phase B. bronchiseptica, 
strain 110 NH, was used for promoter selection to avoid selection of bvg-regulated 
promoters. From 2500 clones examined by fluorescence microscopy, one was identified 
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which expressed GFP. The bacteria expressing GFP were bright green, when examined 
by fluorescence microscope (Figure 1, appendix). Upon restriction digestion of that 
clone, it was determined that the chromosomal DNA upstream to the gfp gene was 
approximately 3kb. Restriction analysis was performed using enzyme sites within the 
multiple cloning sites of pBBR1MCS2, flanking the gfp gene, to further reduce the size 
of the insert. The gfp gene with the cloned upstream promoter region was digested with 
EcoRV and EcoRI and the resulting 1.25 kb fragment was subcloned into the respective 
sites of pBBR1MCS2 to obtain pBBRP9GFP. This plasmid was used in all downstream 
experiments and the promoter region was designated as P9.  
      DNA sequencing (University of Tennessee, DNA sequencing facility) was 
performed in the region immediately upstream of the gfp gene. A BLAST search of 
~250 bp of the sequence, identified this region as having 98% identity to the 
cpn10/cpn60 gene of B. pertussis [13]. There was a four base pair difference in the 
region immediately upstream to the -35 sequences. The gene fragment upstream to the 
gfp gene was an in frame fusion of sequence encoding the first 36 amino acids of the 
cpn10 homolog gene, along with its corresponding regulatory sequences. The predicted 
fusion protein contained a 4kd fragment of CPN 10 protein and intact GFP. As observed 
previously in B. pertussis, this region contains sites for s 32 and s 70 as well as a CIRCE 
 (Controlling inverted repeats of chaperonin expression) element [13]. 
      The plasmids pBBRP9GFP,  pBBRFIMGFP, and pBBRTACGFP were 
electroporated into B. bronchiseptica strains 110H, 110NH, R5, Strain 55 and to E. coli 
strain INVF'. All strains of B. bronchiseptica with pBBRP9GFP showed strong green 
fluorescence when examined by fluorescence microscopy; whereas, the fluorescence 
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intensity was much lower in E. coli that harbored this plasmid. E. coli organisms 
carrying PBBRTACGFP were brighter than all B. bronchiseptica strains with the same 
plasmid. B. bronchiseptica strains carrying pBBRFIMGFP had the lowest fluorescence. 
Neither the B. bronchiseptica strain, 110NH, nor E. coli harboring this plasmid had any 
detectable green fluorescence.  
      The efficiency of P9, fim N and tac promoters to drive GFP expression was 
quantitated using flow cytometric analysis. LB broth, Brucella broth and SS broth were 
used for growing bacteria. A histogram showing flow cytometric profiles of fluorescence 
intensity from different promoters in B. bronchiseptica strain 110H is shown in Figure 2. 
All B. bronchiseptica strains consistently expressed very high levels of GFP from P9 
promoter. There was no significant difference in expression of GFP between these 
strains; however, the activity of this promoter was 40-50 fold lower in E. coli than in B. 
bronchiseptica (Figure 3). In E. coli, tac promoter driven fluorescence (X=20) was 2-5 
fold higher than in B. bronchiseptica strains (X=2.5-10) harboring the same plasmid. The 
fim N promoter had low level activity in B. bronchiseptica strains110H (X=2.5), R5 
(X=2.5) and Strain 55 (X= 4.23). However, unlike the P9 and tac promoters, the fim N 
promoter was not active in strain 110NH (X= 1.6) and in E. coli (X=1.9).  The intensity 
of fluorescence measured by FACS analysis of B. bronchiseptica and E. coli cultures 
expressing GFP under the P9 and TAC promoters was the same with each growth 
medium tested. However, when cultivated in SS broth, B. bronchiseptica strains 110H 
(X= 6.3 vs 2.5), R5 (X=5.3 vs 2.5) and Strain 55 (X= 6 vs 4.23) had increased levels of 
GFP expression from the fim N promoter when compared to GFP expression in LB broth. 
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There was no increase in GFP expression from fim N promoter in strain 110NH when 
grown in SS broth. 
      Since heat shock proteins are induced during periods of stress, the effect of stress 
stimuli on GFP expression from the P9 promoter was examined. Heat shock experiments 
were performed as described previously [38]. For all strains, the GFP expression at 25o C 
was 4-5 times lower than at 37o C. However, increasing the temperature from 25oC to 
37oC and 25oC to 42oC for 20 minutes did not have any effect on GFP expression. Also, 
addition of hydrogen peroxide at a final concentration of 0.005 % did not have any effect 
on GFP expression.  
Adherence assay 
      Adherence assays were characterized based on GFP expression from the P9 promoter. 
Vero cells with adherent bacteria were examined by fluorescence microscopy and flow 
cytometry. Consistent with our previous observation [17], using a conventional adherence 
assay, the Bvg +, virulent phase strain, 110H, adhered well to Vero cells (Figure 4) but 
Bvg-, avirulent phase, strain 110NH did not. Quantitation of the mean intensity of 
fluorescence by FACS analysis showed that strain110H adhered 7-13 times more than the 
avirulent phase, strain 110NH (Figure 5).  
Plasmid stability and growth rate 
      The expression of GFP in overnight LB broth culture was examined with and with out 
antibiotic selection. All strains of B. bronchiseptica expressed equivalent levels of GFP 
from the P9 promoter under selective and non-selective conditions. In vitro stability of 
pBBRP9GFP was tested by continuous passage of the bacteria in non-selective medium 
(Tryptic Soy Agar). When bacteria were examined by fluorescence microscopy, all four 
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strains of B. bronchiseptica failed to sustain the fluorescence after five passages at 48-
hour intervals (~10days) in non-selective medium. This loss of GFP expression was 
associated with plasmid loss, since the recombinant organism could not be recovered in 
antibiotic selection media.  The plasmid was very stable in E. coli, showing green 
fluorescence even after 10 repeated passages on non-selective agar medium. There was 
no difference in growth rate of B. bronchiseptica strains expressing GFP compared to the 
wild-type organisms (Figure 6) indicating that GFP expression did not have any adverse 
effects on bacterial growth. The growth curves were similar for 110H, 110NH and R5; 
whereas a longer lag phase was observed for Strain 55. All strains also had a longer lag 
phase in SS broth than in LB broth or Brucella broth. At 3 hrs post inoculation, GFP 
expressing bacteria were visualized in cryosections of the lung and trachea by confocal 
microscopy. Green fluorescent bacteria were adherent to the ciliated epithelium of the 
trachea and bronchioles (Figure 7). In alveolar spaces bacteria were associated with cells, 
probably macrophages, but were not seen free in the lumen. At subsequent time periods 
after 3hr, fluorescent bacteria were not detected in respiratory tracts of mice that had been 
inoculated with B. bronchiseptica 110H harboring pBBRP9GFP.  
Discussion  
      This report describes the identification and characterization of a promoter useful for 
heterologous antigen expression in B. bronchiseptica utilizing a green fluorescent protein 
reporter system. GFP has been successfully utilized as a reporter gene in several species 
of bacteria [19, 29, 36, 37, 38]. GFP expression in prokaryotes is becoming a widely used 
and easy tool to study various aspects of development, metabolism, gene expression and 
pathogenesis [36, 37]. This is the first report of utilizing this system in B. bronchiseptica. 
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In the related species, B. pertussis, GFP expression for the study of phagocytosis was 
more efficient than tagging the organism with FITC [40]. 
      Bacterial heat shock proteins are abundantly produced throughout the life cycle of 
most bacteria and their synthesis is often increased during periods of stress [21]. In B. 
pertussis the CPN 60 protein exhibits immunological and structural similarities to GroEL 
protein of E. coli, which functions as a molecular chaperone [5, 7]. Complete cloning and 
inactivation of the cpn10/60 homolog gene has to be done to understand the exact 
function of this protein in B. bronchiseptica. However, this study demonstrates the utility 
of this promoter region in heterologous antigen expression. Under normal laboratory 
incubation cond itions, using common media, there was high level expression of GFP 
from the P9 promoter. Stimuli required for P9 promoter activity have not been identified. 
As reported in E. coli [1], it is possible that heterologous protein expression may itself act 
as a stimulus for promoter function. Recent studies indicated a role of CIRCE element as 
a negative regulator involved in inducing stress response [27, 44]. As suggested by Weiss 
et al. [13], one speculation about the presence of binding sites for both s 70 and s 32 
subunits is that organisms may switch these promoter regions under stress and non-stress 
conditions. HSP promoters have been useful in heterologous antigen expression and 
immunogenicity studies with a number of bacteria [3, 38]. In spite of the concern that use 
of HSP as a vaccine component might lead to the generation of an autoimmune response 
due to the highly conserved nature of HSP's among eukaryotes and prokaryotes, 
microbial HSP's have been successfully employed as carrier molecules for peptide 
immunization [43]. The binding affinity of HSP's for peptides and their involvement in 
antigen processing may enhance specific immune responses [43]. The mucosal immune 
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response to heterologous antigens expressed in B. bronchiseptica from the P9 promoter 
and the effect of the remaining 4kD CPN peptide in the P9 promoter-GFP fusion awaits 
further study. 
      The E. coli based promoter tac is widely used in E. coli expression systems. In this 
study, GFP was expressed constitutively from this promoter since the E. coli strain we 
used, and B. bronchiseptica do not possess a lac repressor gene. The tac promoter has 
previously been utilized in B. bronchiseptica to study the expression of adenylate cyclase 
toxin [22]. Although, the level of expression of GFP from the tac promoter in B. 
bronchiseptica was much lower than that from the P9 promoter, heterologous antigen 
expression from tac may have value in inducing an in vivo immune response. It was 
observed in a Vibrio cholerae based heterologous antigen expression system that, the tac 
promoter was better suited for generation of an in vivo immune response than both a HSP 
promoter and an iron regulated promoter [16]. 
      This study is the first to demonstrate functional activity of the fim N promoter in  
B. bronchiseptica. This newly reported fimbrial gene sequence variant has serologic cross 
reactivity with serotype 2 fimbriae of B. pertussis [17]. The reason for low-level 
expression of GFP from fim N promoter is currently unknown. The length of cytosine 
residues (C-stretch) in the promoter region plays a role in optimal transcription of bvg-
regulated genes [34, 41]. The fim N gene cloned in E. coli has two less cytosine residues 
than its chromosomal counterpart [17]. Manipulation of the C-stretch may be another 
strategy to improve the expression of proteins from this promoter. Surface expression of 
heterologous antigens may have great advantage in improving antigen presentation and 
immune responses. Live bacterial vectors and their adhesins are attractive candidates for 
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improving mucosal vaccination strategies [28]. Among B. bronchiseptica adhesins, 
fimbriae are shown to have immunomodulatory effects following intranasal inoculations 
in mice [23]. The molecular chimerization of fim N with a Mannheimia haemolytica 
leukotoxin fragment induced enhanced leukotoxin neutralizing antibody response in mice 
immunized with this recombinant protein [30]. A recent report described the advantage of 
over expression of a protective antigen as a novel approach to improve vaccine efficacy 
[38]. The P9 promoter could be utilized to express fusion proteins of FIM N with other 
protective antigens. Since fimbrial proteins are abundantly produced on bacterial 
surfaces, chimeric fimbriae expressing epitopes from different pathogens seem to be an 
attractive strategy for vaccine delivery. Host species specificity of fimbriae could be 
selectively utilized to deliver antigens to a target species [6]. Two recent studies show the 
effectiveness of B. pertussis fimbriae as a carrier protein for conjugate vaccines [11, 31].  
      There was an increase in expression of GFP from the fim N promoter, when cultivated 
in SS broth, a commonly used medium for vaccine preparation [35]. A similar increase in 
expression of filamentous haemagglutinin when cultivated in SS broth was recently 
reported [18]. The potassium, sodium and chloride ion content of this mineral salts 
medium may be upregulating the Bvg-controlled fim N promoter [10]. 
      The original pBBR1, a broad host range cryptic plasmid isolated from B. 
bronchiseptica [2], was stable without continuous antibiotic selection in Brucella species 
in vitro for >10 days and in vivo in mice for >4weeks [8, 12]. In this study, GFP 
expression from P9 promoter was used as an indicator of in vitro plasmid stability. The 
pBBRP9GFP plasmid was maintained at high to moderate levels for only 4-5 passages 
(10 days) in all the strains tested in the absence of antibiotic selection. Although PBBR1 
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was originally isolated from B. bronchiseptica, the genetic modifications made on the 
pBBR1MCS2 from the original plasmid or hetrologous antigen expression, itself, may 
affect plasmid stability. It is noteworthy that there was no difference in GFP expression 
from these recombinant strains over a period of 24 hours at 37oC under selective and 
nonselective in vitro conditions as measured by FACS analysis.  
      GFP expressing bacteria were not seen in cryosections of the lung and trachea after 3 
hours post inoculation. This might be the result of in vivo plasmid instability or 
repression of the promoter function. The manipulation and processing involved in 
preparing the tissue might have affected the sensitivity of the assay. A modified 
construct, which can stably express GFP, could be utilized for pathogenesis studies 
including the possible long term intracellular survival of this organism. In a subsequent 
study with recombinant B. bronchiseptica that expressed another heterologous antigen 
from the P9 promoter in pBBR1MCS2, only 6.5 % of the total bacteria recovered from 
lungs and trachea of mice retained resistance to the selective antibiotic marker, 
kanamycin, at 24 hours post inoculation, while colonization of plasmid-cured B. 
bronchiseptica continued as long as 56 days post inoculation. Thus, improved plasmid 
stability or construction of chromosomal co-integrates may be required to generate an 
effective immune response to heterologous antigens. 
      The adherence assay utilizing FACS analysis of GFP expression from the P9 
promoter is a more rapid and convenient way of quantitating adherence as compared to 
conventional techniques. Since the adherence of B. bronchiseptica is an important 
virulence property, this assay could be effectively utilized to compare the virulence of 
different strains or to evaluate immune responses to vaccine preparations by attachment 
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inhibition assay. In conclusion, the promoters characterized in this study, may be useful 
for expression of different protective microbial antigens in B. bronchiseptica. The 
potential for utilizing B. bronchiseptica as a mucosal vaccine vector is currently under 
investigation. 
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Figure 1 
B. bronchiseptica strain 110NH expressing GFP from P9 promoter. Visualized by 
fluorescence microscopy. Magnification X1000. 
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Figure 2 
Flow cytometric profiles of GFP expression in B. bronchiseptica strain 110H harboring 
different recombinant plasmids. (A) pBBRGFP (promoter-less), (B) pBBRP9GFP (P9 
promoter), (C) pBBRFIMGFP (fim N promoter), (D) pBBRTACGFP (tac promoter). 
Intensity of the fluorescence on the x-axis indicates the level of GFP expression. X = 
Mean fluorescence intensity.  
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Figure 3 
Comparison of GFP expression from P9 promoter in four different strains of  
B. bronchiseptica and E. coli. The cultures were grown in LB broth and processed as 
explained in materials and methods for flow cytometry. The intensity of GFP expression 
from each strain is represented by mean fluorescence intensity as calculated by 
CELLQUEST Software. B.bronchiseptica strains harboring pBBRGFP were used as 
negative control 
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Figure 4 
Fluorescence microscopic image of Vero cells with adherent bacteria.   
Vero cells were treated with B. bronchiseptica 110H   harboring pBBRP9GFP and 
visualized by fluorescence microscopy.  Magnification X1000. 
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Figure 5 
Bar graph showing the level of adherence of B. bronchiseptica strain 110H and 110NH 
harboring pBBRP9GFP to Vero cells. The values on y- axis indicate mean fluorescence 
intensity as measured by flow cytometry analysis of Vero cell suspensions treated with 
bacteria. Untreated Vero cells similarly incubated were used as negative controls 
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Figure 6 
Comparison of growth curves for wild type and recombinant B. bronchiseptica.   
Overnight cultures of   B. bronchiseptica 110H with pBBRP9GFP and pBBRGFP were 
inocula ted into LB broth containing kanamycin. Wild-type 110H was similarly 
inoculated into LB broth without kanamycin. At designated time points A590 was 
measured and recorded. 
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Figure 7 
In vivo GFP expression in B. bronchiseptica. (A) Bright field image of 8mm cryosection 
of trachea of mouse 3 hours post inoculation with B. bronchiseptica 110H harboring 
pBBRP9GFP. (B) Corresponding confocal scanning image of section seen in A with GFP 
expressing bacteria attached to the ciliated epithelium. Magnification X630 
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                                                       PART 3 
Mouse inoculation studies, Immunization of mice with 
recombinant Bordetella bronchiseptica expressing Pasteurella 
multocida toxin fragment or green fluorescent protein
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Abstract 
      Bordetella bronchiseptica colonizes ciliated epithelium of the upper respiratory tract 
of a wide variety of mammals. The role of Bordetella bronchiseptica and  
Pasteurella multocida toxin in the disease, atrophic rhinitis, of pigs is well documented. 
In this study, a non-toxic, protective P. multocida toxin fragment (PMTCE) and green 
fluorescent protein (GFP) were expressed in B. bronchiseptica from genes cloned into a 
broad-host-range plasmid vector, PBBR1MCS2, and placed under the control of a 
promoter region isolated from B. bronchiseptica that appears to be a member of the heat 
shock protein gene family. While wild-type and recombinant B. bronchiseptica colonized 
the mouse respiratory tract effectively, the plasmid was no longer detected from the 
organism after 72 hours post- inoculation. After a single intranasal inoculation, IgM, IgA 
and IgG responses to B. bronchiseptica were detected in serum and broncheoalveolar 
lavage samples. PMTCE specific antibodies were not detected. Four intranasal 
inoculations with   B. bronchiseptica expressing green fluorescent protein induced 
systemic and mucosal immune responses to GFP; however, similar inoculations with B. 
bronchiseptica expressing the PMTCE fragment did not induce detectable PMTCE 
specific immune responses.  
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Introduction 
      Atrophic rhinitis (AR) is an upper respiratory tract disease of pigs characterized by 
degeneration and atrophy of nasal turbinate bones leading to visible distortion and 
shortening of the snout [9, 28]. This disease is of major economic importance to pig 
breeders all over the world. Bacterial etiologies identified in this condition are toxigenic 
strains of Pasteurella multocida and virulent strains of Bordetella bronchiseptica, alone, 
or combined with environmental factors like dust, ammonia and other physical or 
chemical irritants [2, 6, 10, 26, 29]. Pasteurella multocida is an important veterinary 
pathogen involved in diseases such as atrophic rhinitis in swine, fowl cholera in birds, 
hemorrhagic septicemia in cattle and other respiratory diseases in lab animals [2]. Many 
capsular type D and occasional type A strains of   P. multocida produce a potent, 
intracellular, heat- labile, 146Kd, mitogenic toxin (PMT), which is a major virulence 
factor in atrophic rhinitis [5, 6, 11]. The role played by P. multocida and B. 
bronchiseptica in AR is documented in a number of experimental studies [3, 4, 19, 27]. 
B. bronchiseptica, is widely distributed in swine herds with  and without atrophic rhinitis. 
The infection with B. bronchiseptica can lead to mild non-progressive forms of atrophic 
rhinitis that do not affect growth rate [6].  Toxigenic type D P. multocida is the most 
common isolate in severe, progressive, growth retarding atrophic rhinitis [6]. 
Experimental inoculation of pigs with cell- free extracts of P. multocida or purified toxin 
can also lead to severe, progressive atrophic rhinitis [11]. Experimental infections in 
gnotobiotic pigs implicate that colonization with virulent strains of B. bronchiseptica 
damages the nasal mucosa and predisposes animals to colonization by toxigenic P. 
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multocida [3, 4]. By itself, P. multocida does not readily colonize the nasal mucosa. 
Vaccination and good management practices are the main approaches used to control this 
condition [6]  
      Considering the proposed synergistic role of B. bronchiseptica and P. multocida in 
AR, and the common usage of live-attenuated B. bronchiseptica vaccines and P. 
multocida toxoid/ bacterins to control AR, further refinements of combined vaccines are 
warranted. In this study, a non-toxic protective fragment of PMT and green fluorescent 
protein (GFP) were expressed in B. bronchiseptica. Colonization kinetics, plasmid 
stability and immune responses generated to B. bronchiseptica, PMT, and GFP were 
evaluated in mice. 
Materials and methods 
Plasmids, bacterial strains, and enzymes  
      Origin of the B. bronchiseptica strains used in this study has been previously 
described [1]. Strain 55 is a live attenuated B. bronchiseptica (ATCC 31437) vaccine 
strain. Luria Bertani (LB) agar or broth with appropriate antibiotic selection at 37oC were 
the conditions employed to grow all bacteria unless otherwise indicated. Smith 
Baskerville medium was used for isolation of B. bronchiseptica from mouse respiratory 
tract samples [23]. Restriction enzymes and LA Taq polymerase were products of 
PANVERA, Madison WI. Wizard plus SV miniprep kit (Promega, Madison WI) was 
used for plasmid isolation. The plasmid, pBBR1MCS2, (kindly provided by Kovach, M. 
E) [12] was used for cloning and expression of the GFP gene and the PMT gene 
fragment. A promoter region (P9) with homology to heat shock gene promoter region of 
B. pertussis was isolated from B. bronchiseptica using a green fluorescent protein 
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reporter system. This promoter was previously used to drive high- level expression of 
GFP in four different strains of B. bronchiseptica [S. Rajeev, Dissertation, Part 2]. The 
PMT gene fragment (PMTCE) consisted of base pairs 1999-4055 encoding the C-
terminal 685 amino acids of PMT. This fragment was amplified from genomic DNA of 
P. multocida (NCTC 12178) using LA Taq polymerase and primers 5'-
CGGGATCCCGTTATTGGAAAGCCTATTGGA-3' (forward) and 5'-
GGGGATCCGTTATAGTGCTCTTGTTAAGCG-3'(reverse). The PMTCE fragment 
was cloned into BamHI digested and calf intestinal alkaline phosphatase treated   
pBBRP9. The ligation mixture was transformed into E. coli and transformants were 
selected on LB plates containing kanamycin (100mg/ml). The correct insertion of the 
sequence was verified by restriction digestion with enzymes that cut within the PMTCE 
fragment. Expression of PMTCE was detected on western blots of whole cell lysates 
using PMT specific monoclonal antibody, Mab CRL1965, obtained from ATCC [13]. 
The resulting plasmid construct with PMTCE- promoter fusion was electroporated into B. 
bronchiseptica strains 110H, 110NH, R5, strain 55 using a CELL-PORATOR 
Electroporation system (GIBCO-BRL, Gaithersburg, MD) following manufacturer's 
instructions.  Electroporants were selected on kanamycin plates and tested for the 
expression of PMTCE by Western blotting. 
SDS-PAGE and Western blots 
      SDS-PAGE was performed using 10 % polyacrylamide gels (Ready Gels, Bio-Rad, 
Hercules, CA) according to standard procedures. An overnight culture of each  
B.bronchiseptica strain containing the recombinant plasmid, PBBRP9PMTCE, was 
adjusted to an optical density (A590) of 0.5. One hundred ml of this suspension was 
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centrifuged at 5000 rpm for one minute. The pellet was suspended in 100ml of 1x sample 
buffer (Sigma Chemical Company, St. Louis, MO) and boiled for 10 minutes. Aliquots of 
5ml were loaded to 10% polyacrylamide gels. The gels were electrotransferred to 
nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk 
solution in phosphate buffered saline with 0.05%Tween 20(PBS-T) for 30 minutes and 
then reacted with a 1mg/ ml solution PMT specific monoclonal antibody, CRL 1965, in 
1% nonfat dry milk in PBS-T for one hour. The membranes were washed four times in 
PBST for 30 minutes and incubated with 1/10,000 dilution of peroxidase-conjugated anti-
mouse IgG (Sigma Chemical Company). After washing four times in PBS-T for 30 
minutes, the membranes were developed with chemiluminescent substrate  
(SuperSignal R West Pico Substrate Pierce, Rockford, IL)  and the membranes were 
exposed to CL-XposureTM Film (Pierce, Rockford, IL) following the manufacturer's 
guidelines. 
 Intranasal inoculation of mice  
       Four to six week-old female BALB/c mice were obtained from Harlan Laboratories 
(Indianapolis, IN) and maintained by routine procedures in an AALAC accredited animal 
facility. Groups of 3-4 mice were inoculated with ~ 1x10 5 CFU of either wild-type B. 
bronchiseptica 110H or recombinant B. bronchiseptica 110H harboring pBBRP9PMTCE 
or pBBRP9GFP. Mice were anaesthetized by Isoflurane (Abbott Laboratories, North 
Chicago, IL) and 50ml of the inoculum was instilled into the nostrils. Mice were also 
similarly immunized with B. bronchiseptica expressing GFP from the same promoter. In 
a second experiment, mice, inoculated once by the intranasal route with 1x10 5 CFU were 
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boosted three times at biweekly intervals via the intranasal route with 1x107   CFU of each 
respective strain of B. bronchiseptica expressing GFP or PMTCE. An additional group of 
mice primed with B. bronchiseptica expressing GFP were given a single intranasal 
inoculation with 50 mg of purified recombinant GFP in PBS. 
Colonization kinetics and in vivo plasmid stability 
      Mice were sacrificed at designated time points and the entire lungs and trachea 
 were collected  aseptically. The tissue was homogenized and serial dilutions were plated 
onto Smith Baskerville media with and without kanamycin. The plates were incubated for 
48 hours at 37 oC and colony counts were performed. The percentage of kanamycin 
resistant B. bronchiseptica colonies compared to the total number of colonies recovered 
on non-selective media was calculated. The colonization studies were continued until the 
colony counts reached minimum detectable levels (56 days). 
Antibody response 
      Mice were bled from the retro-orbital sinus on 14, 28, 42 and 56 days post- 
inoculation. Nasal and broncheoalveolar lavage (NBAL) were collected at the same time 
points using a 24-gauge teflon catheter by flushing the lung, trachea and nasal cavity with 
2 ml of PBS. Pooled samples were centrifuged at 3000 rpm to remove particulate matter. 
Lavage samples and sera were stored at -70oC until further evaluation. Lavage samples 
that were visibly contaminated with blood were discarded. 
       A kinetic enzyme linked immunosorbent assay (KELISA) was performed to evaluate 
the antibody response to B. bronchiseptica and PMTCE. In brief, 96-well plates 
(Immulon 2HB, Dynex) were coated overnight either with a suspension of B. 
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bronchiseptica (strain 110H grown on TSA and adjusted to optical density, A590, of 0.1 
in PBS), purified recombinant PMTCE (10mg/ ml in PBS) or purified recombinant GFP  
(10 mg/ml). Plates were washed four times in PBS-T and blocked for 30 minutes with 
PBS-T. One hundred ml of serum (1/40 dilution) or undiluted NBAL was added to plates 
and incubated for 2 hrs at 37oC. Plates were washed four times with PBS-T and incubated 
with peroxidase-conjugated secondary antibodies, anti-mouse IgG (1/2000), IgM 
(1/1000), and IgA (1/1000) in PBS-T. Plates were washed four times with PBS-T and 
developed with 100ml of substrate solution, 2,2'-azino diethylbenzothiazoline-6-sulphonic 
acid (ABTS, Sigma Chemical Company, St Louis MO) and hydrogen peroxide. The 
plates were read kinetically at A405 using ELx800 ELISA reader (BIO-TEK instruments 
Inc., Winooski, VT). The plates were read 7 times at one-minute intervals, the maximum 
slope (KELISA slope is directly proportional to the amount of antibody bound) was 
calculated using KCjunior software (BIO-TEK instruments Inc, Winooski, VT) 
 Statistical analyses 
          The significance of differences between groups was determined by Student’s t-tests. 
The data are expressed as mean +/- standard error of mean. P values < 0.05 were 
considered significant. 
Results 
Cloning and expression of PMTCE in B. bronchiseptica 
      Initial attempts to express a previous ly reported 125kD, non-toxic, N-terminal 
deletion mutant of PMT [21, 22] were unsuccessful. The recombinant 
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 B. bronchiseptica harboring this plasmid exhibited marked reduction in growth in vitro 
and did not show any expression of this protein on immunoblots. We have identified N- 
terminal and C-terminal recombinant PMT protein fragments which can protect mice 
from lethal challenge with PMT [20]. Intraperitoneal immunization with these proteins in 
Freund's incomplete adjuvant elicited high level of anti-PMT antibodies and protected 
mice from intraperitoneal challenge with P. multocida toxin [20]. The C-terminal 
protective fragment (PMTCE) was utilized for expression in B. bronchiseptica.  
A schematic representation of the expression plasmid is given in Figure 1(appendix). A 
PMT specific monoclonal antibody, CRL-1965, was used for detection of expression of 
this protein in B. bronchiseptica [13]. PMTCE expression was initially detected in 
electroporants of all strains of B. bronchiseptica and in E. coli. After storage at -70oC, 
repropagation and examination, B. bronchiseptica strain 55 no longer produced a reactive 
protein band on western blot. The expected protein band of 80kD (76kD PMTCE+ 4kD 
from the promoter region) was seen on Western blot with chemiluminiscent substrate 
(Figure 2). However, the bands were not visible in Western blots developed with 
colorimetric substrate, indicating that the amount of protein produced was low. The 
amount of protein in each band was quantitated on Western blots by un-SCAN-IT TM 
(Silk Scientific Corporation).  B. bronchiseptica strains 110H, 110NH,  and R5 expressed 
6.4mg/0.5OD/ml , 6.2mg/0.5OD/ml, and 74mg/0.5OD/ml, respectively. Each strain that 
expressed PMTCE and affinity purified PMTCE had a second immunoreactive band that 
is presumed to be a degradative fragment. Such fragments have been previously reported 
in purified native and recombinant PMT [20]. A third non-specific band was observed in 
all samples including the negative controls indicating possible cross reactivity of the 
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monoclonal antibody with some component in B. bronchiseptica. Expression of PMTCE 
in B. bronchiseptica did not affect the growth in vitro (Figure 3). 
Plasmid stability and colonization kinetics 
      The proportion of plasmid bearing recombinant B. bronchiseptica in lungs and 
trachea of mice was determined by comparing the number of B. bronchiseptica CFU 
obtained on Smith Baskerville medium with kanamycin selection to the number of B. 
bronchiseptica CFU obtained on Smith Baskerville without kanamycin selection.  B. 
bronchiseptica was not isolated from any of the uninfected mice. The percentage of 
kanamycin resistant colonies recovered from mice is shown in figure 4. Forty five percent 
of the colonies harbored recombinant plasmid at 1hr post- inoculation. This frequency 
gradually decreased to 0.007% at 72 hours post- inoculation. Recombinant and wild type 
B. bronchiseptica colonized the respiratory tract of mice (Figure 5). The number of 
organisms recovered increased until 7 days post- inoculation and gradually decreased 
thereafter. By day 56, the number of organisms recovered was close to the minimum 
detectable levels. There was no significant difference (p<0.05) in the total number of 
organisms recovered at any time point from mice inoculated with wild-type or 
recombinant B. bronchiseptica.  However, colonization of wild-type and recombinant 
B. bronchiseptica can not be compared because of the rapid loss of the plasmid.  
Antibody response in mice 
      Antibody responses generated against B. bronchiseptica and the heterologous 
antigens, PMTCE and GFP after intranasal inoculation with live B. bronchiseptica were 
evaluated by KELISA [15, 30, 31]. KELISA measures the rate of color development 
during the initial period of reaction, and is represented by the maximum slope, which is 
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directly, proportional to the amount of secondary antibody conjugate bound. KELISA 
performed using a single serum dilution was reported to be as sensitive and specific as 
determining the endpoint titer [30]. IgG, IgA and IgM levels were measured in individual 
serum samples and pooled NBAL samples. A single intranasal inoculation with wild-type 
and recombinant B. bronchiseptica induced marked B. bronchiseptica specific antibodies 
in the serum and NBAL (Figure 6) 
       B. bronchiseptica-specific serum IgM levels  were detected at 14 day post 
inoculation and  remained stable throughout the period analyzed. Serum IgG levels 
increased gradually in wild-type and recombinant B. bronchiseptica inoculated mice. The 
serum IgG, levels to B. bronchiseptica were significantly higher (p= >0.05) in groups 
inoculated with wild-type organisms compared to B. bronchiseptica expressing PMTCE. 
An increase in B. bronchiseptica specific serum IgA levels was also detected in the 
serum. In the NBAL an initial increase in IgM levels were followed by stable levels.  
B. bronchiseptica specific IgG  and IgA were also observed in NBAL. The PBS 
inoculated controls did not produce any antibody response to B. bronchiseptica. 
      A single intranasal inoculation with recombinant B. bronchiseptica either expressing 
GFP or PMTCE did not induce detectable antibody responses to the respective proteins.  
In a second experiment, mice were first inoculated with 1x105 CFU of B. bronchiseptica 
virulent strain, 110H or avirulent strain, 110NH expressing GFP or PMTCE by the 
intranasal route followed by three intranasal booster inoculations with 1x107 organism at 
14 day intervals. 
      After initial inoculation, 110H (Bvg+) infected mice became sick (characterized by 
raised hairs and lethargy) and recovered by third day. However, mice inoculated with 
 116 
110NH (Bvg -) were normal. Even though inoculation with 1x105 B. bronchiseptica 
110H produced transient illness in mice, mice initially inoculated with 1x105 B. 
bronchiseptica 110H did not suffer any ill effects following intranasal exposure to 1x108 
organisms 14 days later. Mice that had not received the initial exposure to 1x105 
organisms died within 72 hours after intranasal exposure to 1x107 CFU of B. 
bronchiseptica strain 110H. Multiple inoculations with higher number of organisms were 
done to provide increased exposure to the heterologous antigens. 
      A PMT-specific immune response was not observed after exposure to the increased 
number of organisms. However, a GFP-specific antibodies were obtained in NBAL and 
serum after boosting with the increased dose of B. bronchiseptica 110H expressing GFP 
(Figure 7). Serum GFP antibodies were predominantly of IgG subclass and NBAL GFP 
antibodies were a mixture of IgA and IgG. Mice inoculated with avirulent 110NH and 
boosted similarly did not produce detectable serum antibodies to GFP. There was a slight 
increase in GFP-specific IgA in NBAL.  When mice inoculated with recombinant B. 
bronchiseptica strain 110H expressing GFP were boosted with 50mg of purified 
recombinant GFP, high levels of GFP antibodies were observed in serum (Figure 8). 
GFP-specific response was predominantly IgG. A similar increase in GFP-specific 
response was not noticed in NBAL.  
Discussion 
      Atrophic rhinitis is a disease of significant economic importance to US agriculture. 
Vaccines against atrophic rhinitis consist of killed or live preparations of B. 
bronchiseptica along with P. multocida bacterins or toxoid. Development of a safe and 
bivalent live vaccine with avirulent B. bronchiseptica that expresses protective epitopes 
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of PMT would represent a novel approach to control this disease. This is the first study to 
demonstrate expression of a foreign protective antigen in B. bronchiseptica and the utility 
of B. bronchiseptica as a mucosal vaccine vector directed to the respiratory tract. 
A single intranasal inoculation with recombinant and wild-type B. bronchiseptica   
induced both systemic and mucosal immune responses to B. bronchiseptica. While IgG 
was the predominant antibody in the serum, IgA predominated in NBAL. In a recent 
report, mucosal IgA antibodies against B. bronchiseptica were observed after intranasal 
inoculation of mice with B. bronchiseptica and authors of this paper hypothesized that 
this lack of mucosal IgA response was due to the toxins secreted by the type III secretion 
machinery [14] 
      Plasmid instability leading to insufficient antigen exposure may have been the most 
important factor responsible for our initial inability to detect an antibody response to 
PMTCE and GFP after a single intranasal inoculation with recombinant B. bronchiseptica 
expressing these proteins. It was hypothesized that booster inoculations with increased 
numbers of organisms will provide increased exposure to the preformed fo reign antigens 
contained in the inoculum. An antibody response was observed for GFP but not PMTCE.  
The inability to detect antibodies to PMTCE compared to GFP after booster inoculations 
might be attributed to the comparative low-level expression of PMTCE, plasmid 
instability or antigenic differences of PMTCE expressed in B. bronchiseptica. The yield 
of PMTCE in the E. coli expression system was also very low [20]. Therefore, production 
and purification of large quantities of PMTCE is difficult and identifying stable 
protective fragments of PMT for expression in B. bronchiseptica is worthwhile to pursue. 
Recently, we have shown that the molecular chimerization of Fim N protein of  
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B. bronchiseptica with an unstable protective fragment of leukotoxin of Mannheimia 
haemolytica augmented neutralizing antibody response to leukotoxin [24]. Stabilization 
of a PMT fragment by combining it with FIM N may also enhance the immune response 
to PMT. An intranasal dose of 1x105 CFU could be given to mice without causing any 
deleterious effects. Increasing the number of organisms in unprimed animal's lead to 
100% mortality. We could inoculate with a 100 times greater dose of 
B. bronchiseptica in previously exposed mice, without any deleterious effects. A 
protective immune response in mice against B. bronchiseptica was probably generated as 
early as 14 days. Four inoculations with B. bronchiseptica 110H expressing GFP induced 
significantly greater GFP-specific antibody responses in the serum and NBAL than 
110NH expressing GFP. B. bronchiseptica 110H is a Bvg+ strain which effectively 
colonizes the respiratory tract where as Bvg- strains, like 110NH, do not have the 
capability to colonize. The difference in immune responses to GFP in 110H and 110NH 
infected mice suggests that, colonization played an important role in the generation of 
immune response against GFP. In addition to simply influencing the level of antigen that 
the immune system was exposed to, it is also possible, as previously suggested [14], that 
adhesins and other virulence factors produced by B. bronchiseptica colonization may 
have produced immunomodulating effects. 
      A second intranasal inoculation with recombinant GFP, after initial inoculation with 
B. bronchiseptica 110H expressing GFP induced systemic GFP-specific antibodies; 
whereas, control animals inoculated with GFP in PBS did not. This increase in response 
indicates that there was a priming effect after inoculation with B. bronchiseptica 110H 
expressing GFP, but not with 110NH that expressed GFP. Intranasal priming with 
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recombinant B. pertussis and subsequent intranasal boosting with the foreign antigen 
resulted in an effective systemic response against the foreign antigen [16]. Our 
experiment gave similar results and suggests that this mode of immunization could be 
utilized to generate systemic humoral immune responses against specific protective 
antigens.  
      Virulent B. bronchiseptica is unsuitable for field vaccination purposes. The creation 
of selected mutations in virulence genes like adenylate cyclase toxin and dermonecrotic 
toxin, along with chromosomal integration of the genes encoding the foreign antigen may 
be ideal. In B. pertussis, chromosomal integration was utilized for expression of a 
heterologous antigen  [17, 25]. Improving the stability of the plasmid vector by 
construction of balanced lethal vectors as described in Salmonella [7] or by incorporating 
a post-segregational killing function without manipulation of the live host can be done 
[18]. While chromosomal integration may stabilize expression, it usually leads to low 
level expression, which can result in sub-optimum immune responses. Stable multicopy 
plasmid vectors can overcome this by the overexpression of antigen needed to generate 
an effective immune response [8]. 
      Identification of essential protective antigens and improved delivery of vaccine 
components is essential for future vaccine development. Live-attenuated B. 
bronchiseptica vaccines are widely accepted in animals and molecular methods to 
genetically inactivate unwanted traits are available; therefore, construction of a live B. 
bronchiseptica that expresses protective PMT antigens is desirable from the standpoint of 
both safety and efficacy. Further manipulations of host strain, improvements in plasmid 
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stability and stabilization of heterologous antigen expression are essential to make this 
system effective. 
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Figure 1 
Schematic representation of recombinant plasmid vector pBBR1MCS2 expressing  
P. multocida toxin fragment (PMTCE). Restriction sites used to clone in the fragment are 
indicated. P9 is a constitutive promoter cloned upstream to PMTCE in frame to drive the 
expression of the PMTCE.               
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Figure 2 
Expression of PMTCE in B. bronchiseptica.  
Whole cells harboring the recombinant plasmid were subjected to SDS PAGE on a 
10%polyacrylamide gel and electro- transferred to nitrocellulose membrane. Membranes 
were probed with PMT specific monoclonal antibody, CRL-1965 and developed with 
chemiluminescent substrate. Numbers on the left indicate the approximate positions of 
prestained molecular weight markers in kilo Daltons. Lanes 1,3, 5, and 7 are lysates of  
B. bronchiseptica strains 110H, 110NH, R5, and 55 harboring pBBRP9 without PMTCE 
insert respectively. Lanes 2, 4, 6, and 8 contains lysates of B. bronchiseptica strains 
110H, 110NH, R5, and 55 harboring pBBRP9PMTCE. Lane 9 contains 50ng of affinity-
purified recombinant PMTCE.
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Figure 3 
Comparison of growth curves 
Overnight cultures of the recombinant B. bronchiseptica strain 110H harboring pBBRP9 
and pBBRP9PMTCE were inoculated into LB broth containing kanamycin. Wild-type 
 B. bronchiseptica was also similarly inoculated into LB broth without kanamycin. 
 At designated time points optical densities at A590 were measured and recorded. 
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Figure 4 
In vivo stability of the recombinant plasmid in B. bronchiseptica. 
 Mice were inoculated with 1x105 B. bronchiseptica in PBS via the intranasal route. At 
designated time points lungs and trachea were aseptically collected and homogenized, 
serial dilutions were plated on to Smith Baskerville media with and without kanamycin. 
The percentage of kanamycin resistant colonies in relation to the total number of colonies 
recovered is reported.
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Figure 5 
Colonization kinetics of B. bronchiseptica in mice.  
Mice were inoculated with 1x105 B. bronchiseptica in PBS via the intranasal route. At 
designated time points lungs and trachea were aseptically collected and homogenized, 
serial dilutions were plated on to Smith Baskerville media. Total CFU recovered at 
designated time points is reported.
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Figure 6 
Antibody response to B. bronchiseptica in mice. 
Mice were inoculated via the intranasal route with a suspension in PBS containing 1x105 
wild-type or recombinant B. bronchiseptica110H expressing PMTCE. NBAL and serum 
were collected at designated time points.  IgG, IgM, and IgA responses were measured by 
KELISA and reported as KELISA slope. The day at which the samples were collected is 
given on x-axis. The control animals were inoculated with PBS  
 (A) Serum antibody response to B. bronchiseptica strain 110H in mice inoculated 
with recombinant 110H expressing PMTCE.  
(B) Serum antibody response to B. bronchiseptica strain 110H in mice inoculated 
with wild-type.  
(C) Mucosal antibody response to B. bronchiseptica strain 110H in mice inoculated 
with recombinant 110H expressing PMTCE. 
(D) Mucosal antibody response to B. bronchiseptica strain 110H in mice inoculated 
with wild-type.  
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Figure 7 
Antibody response to GFP 
Mice were inoculated with 1x105 recombinant B. bronchiseptica 110H expressing GFP, 
110NH expressing GFP, 110H expressing PMTCE or PBS via the intranasal route. The 
mice were boosted with 1x107 organisms three times at 14 day intervals.  NBAL and 
serum was collected on the 9th day after final boosting. GFP specific IgG, IgM, and IgA 
response was measured by KELISA and reported as KELISA slope. (A) Serum antibody 
response. (B) Mucosal antibody response 
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Figure 8 
Antibody response to GFP after boosting with recombinant GFP 
Mice were inoculated with 1x105 recombinant B. bronchiseptica 110H, recombinant 
110NH expressing GFP, wild-type 110H, wild-type 110NH or PBS via the intranasal 
route. On the 14th day post- inoculation the mice were given 50mg of GFP in PBS via the 
intranasal route.  NBAL and serum were collected on the 9th day after inoculation with 
GFP. GFP-specific IgG, IgM, and IgA antibodies were measured by KELISA and 
reported as KELISA slope. A) Serum antibody response. B) Mucosal antibody response 
X-axis labels, 1-strain 110H followed by GFP, 2-110NH followed by GFP, 3- 110H 
expressing GFP followed by GFP, 4-110NH expressing GFP followed by GFP, 5- PBS 
followed by GFP, 6- PBS alone.
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immunogenicity of a Mannheimia haemolytica 
leukotoxin fragment 
 146 
 
                 Abstract  
      Leukotoxin produced by Mannheimia (Pasteurella) haemolytica is an important 
virulence factor in shipping fever pneumonia in feedlot cattle and is a critical protective 
antigen. In this study, the immune response to a chimeric protein generated by combining 
a gene fragment encoding neutralizing epitopes of M. haemolytica leukotoxin and a 
fimbrial protein gene (fim N) from Bordetella bronchiseptica was evaluated. The 
recombinant gene was cloned in a bacterial expression vector under the control of the tac 
promoter and expressed as a fusion protein with glutathione-S-transferase (GST) in 
Escherichia coli. Immunization of mice with the recombinant protein, GST-LTXFIM 
elicited a significantly stronger anti- leukotoxin antibody response than comparable 
immunizations with GST-LTX fusion proteins lacking FIM N. The GST-LTXFIM was 
also more stable than GST-LTX during storage at -80oC, thus alleviating a stability 
problem inherent to leukotoxin. This chimeric protein may be a candidate for inclusion in 
new generation vaccines against shipping fever pneumonia.  
 
 
 
 147 
 
Introduction 
       Shipping fever pneumonia in feedlot cattle is a multifactorial disease that results in 
great economic loss in the United States cattle industry. Mannheimia (Pasteurella) 
haemolytica is the primary bacterium associated with this condition. Leukotoxin secreted 
by M. haemolytica is a ruminant leukocyte-specific, pore-forming cytotoxin of the RTX 
(repeat in toxin) family of toxins, and is an important virulence factor of this organism (3, 
6, 8, 29, 31). Protection of cattle from shipping fever pneumonia has been correlated with 
the presence of leukotoxin-neutralizing antibodies (19, 20, 21, 25, 26, 27, 28). However, 
leukotoxin-neutralizing antibody responses induced by current vaccines are highly 
variable, and this disease remains an important health problem in feedlot cattle (28). 
Instability of native leukotoxin has led to difficulty in its purification and limited the 
inclusion of this antigen in vaccine preparations (7). The toxicity of native, biologically 
active leukotoxin may also be a concern for vaccine safety. 
      The gene encoding leukotoxin has been fully sequenced (12) and a number of 
leukotoxin- neutralizing monoclonal antibodies against linear and conformational 
epitopes have been mapped to peptides derived from the carboxy-terminal region of 
leukotoxin (10, 16). A minimal leukotoxin A gene fragment encoding carboxy-terminal 
aminoacids 713-939 was previously characterized and the truncated non-cytolytic 
recombinant protein (LTX) was recognized by three leukotoxin-neutralizing monoclonal 
antibodies (18). Immunization with this recombinant protein in Freund’s complete 
adjuvant (CFA) elicited considerable leukotoxin neutralizing-antibody response in 
rabbits; however, the protein was unstable on storage at -80 oC (18).  
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       Fimbriae are important virulence factors involved in attachment of many Gram- 
negative bacteria to host tissues (15). Fimbrial antigens are highly immunogenic and 
generally abundant on bacterial surfaces. We recently cloned and characterized a novel 
fimbrial gene, fim N, from Bordetella bronchiseptica (14), an upper respiratory tract 
pathogen that affects a wide variety of host animals (4, 11). Adhesins that serve 
colonizing functions in Bordetella spp. may be useful in delivering heterologous antigens 
and several B. pertussis antigens, including pertussis toxin (1, 2), adenylate cyclase toxin 
(23), tracheal colonization factor (5) and filamentous haemagglutinin (22) have been 
expressed as heterologous recombinant proteins. Fimbrial protein from Escherichia coli 
has been documented as effective carriers of heterologous antigens (15).  In the course of 
studying the suitability of FIM N as a heterologous antigen carrier, we observed that a 
LTX-FIM N recombinant fusion protein enhanced the immunogenicity of LTX beyond 
that which had been observed with other LTX recombinant proteins. This report 
describes the construction and immunologic evaluation of a LTX-FIM N recombinant 
fusion protein. 
Materials and methods 
Plasmids, bacterial strains, chemicals and enzymes  
      Plasmids used in this study are described in Table 1. Escherichia coli strains, 
Top10F’ (Invitrogen Inc., San Diego, CA) and BL21-Gold (Stratagene, La Jolla, CA) 
were used for cloning and protein expression, respectively. Restriction enzymes were 
products of Gibco/BRL (Gaithersburg, MD) and New England Biolabs (Beverly, MA). 
Taq polymerase was obtained from PANVERA Corporation (Madison WI). DNAse, 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), and isopropyl b-D- 
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thiogalactopyranoside (IPTG) were purchased from Sigma Chemical Company (St. 
Louis, MO). 
Construction of expression plasmids  
      Polymerase Chain Reaction (PCR) was performed in a Gene Amp PCR system 9600 
(Perkin Elmer, Narcross, GA). The fim N gene (without putative signal sequence) was 
amplified from PCR2-FIM by PCR using primers ECOFWD (5’-
GGGAATTCACGATCGTGATCACCGGCA -3’) and XHOREV (5’-
GGCTCGAGGATTATCCTTATCAAGCC -3’) with engineered restriction sites 
(underlined). The product was digested with XhoI and EcoRI, gel purified (Gel 
Extraction kit, Quiagen, Valencia, CA) and cloned into pGEX-5X-1 that had been pre-
digested with XhoI and EcoRI. The resulting plasmid was named pGEX-FIM. A 663 bp 
fragment of M. haemolytica leukotoxin A gene, encoding amino acids 719- 939, was 
amplified from pGEX-LT FUSION by PCR with primers LTBAMF (5’-
GGGGATCCATAACGATATCTTTAAAGG-3’) and LTECOR (5’-
GGGAATTCCATTGAAGTTGGAGCCAC-3’). Engineered BamHI and EcoRI 
restriction sites are underlined. The PCR product was cloned into BamHI and EcoRI sites 
of pGEX-5X-1 to form plasmid pGEX-LTBE. To construct the plasmid pGEX-LTFIM, 
the EcoRI and XhoI digested fimN fragment from pGEX-FIM was ligated to the EcoRI 
and XhoI sites of pGEX-LTBE. The GST gene was amplified from pGEX-5X-1 vector 
using primers 5’-TATTGGAAAATTAAGGGCCTCGAGCAA -3’and 5’-
TATATACTCGAGGGATTTCAAGTACTT -3’, and cloned into the XhoI site of pGEX-
LT FUSION downstream to leukotoxin fragment. This plasmid was called pGEX-
LTGST. The 5’ and 3’ ends of all constructs were sequenced at the University of 
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Tennessee DNA sequencing facility on an Applied Biosystems 373 automated sequencer. 
All recombinant plasmids were introduced into E.coli BL21-Gold by transformation (16). 
Expression and purification of the recombinant proteins  
       E. coli BL21-Gold cells harboring the expression plasmids were inoculated into one 
liter of LB broth containing ampicillin (100 mg/ml) and incubated at 37oC, with rotary 
shaking (220 rpm), to an optical density (A600)  of 0.6-0.8. Plasmid gene expression was 
induced with IPTG (final concentration, 0.2 mM) and after two hours of further 
incubation, bacteria were harvested by centrifugation at 5000 x g for 10 minutes. The 
pellet was used immediately for protein purification or stored at -80oC until further use. 
GST-LTX was initially purified under non-denaturing conditions according to the 
manufacturer’s (GST Gene Fusion System, Pharmacia, Piscataway, NJ) protocol. 
Subsequent purification of this protein and all other recombinant proteins was performed 
by a modification of the procedure reported by Frangioni and Neil (9). Briefly, cells were 
suspended in 100ml of STE buffer (10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1 mM 
EDTA) with 100 mg /ml of lysozyme. Dithiotreitol (DTT) was added to a final 
concentration of 5 mM, and the cell suspension was incubated on ice for 30 minutes. 
SarkosylTM (N-lauroylsarcosine) was added to a final concentration of 1.5%, and the 
suspension was sonicated for one minute to reduce the viscosity. DNAase (1200U) and 
Triton X-100 (final concentration 1%) were added, and the mixture was incubated on ice 
with intermittent shaking for one hour. After centrifugation  (14,000 x g for 20 minutes), 
the supernatant was mixed with a one ml slurry of 50% GST sepharose (Pharmacia, 
Piscataway, NJ) and incubated at room temperature with gentle shaking for 4 h. The GST 
sepharose was washed four times with PBS (phosphate buffered saline), and bound 
 151 
proteins were eluted with 6 M guanidium chloride in PBS. The eluted fraction was 
dialyzed overnight in PBS. Protein concentrations were determined using the 
Bicinchoninic Acid Assay (Sigma Chemical Company, St Louis, MO). Samples were 
adjusted to contain 1 mg protein /ml in PBS and stored at -80oC until further use. The 
preparations were examined by SDS-PAGE and immunoblotting with leukotoxin and 
fimbriae specific antibodies. 
Animals and Immunizations  
      Four-week old New Zealand White rabbits and 4-6 week old female BALB/c mice 
(Harlan Laboratories, Indianapolis, IN) were maintained by routine procedures in an 
AALAC accredited laboratory animal facility. Rabbits were inoculated with 500 mg of 
recombinant protein (1mg/ml), GST-FIM, GST-LTX or GST-LTXFIM, emulsified in an 
equal volume of Freund’s incomplete adjuvant (IFA). Intramuscular injections were 
given to each rabbit on days 0, 14, 28, and 42, respectively. Blood was collected from 
rabbits on days 0 and 51.  
      Groups of 5-7 mice were immunized with recombinant proteins by intraperitoneal 
injection. Each animal received three 100 ml doses containing 50 mg of antigen. Antigens 
used for the first injections were given with an equal volume of CFA, IFA or PBS. 
Booster injections given on day 14, were in IFA or PBS, and final injections on day 35 
were given in PBS. A control group received CFA + PBS as the first injection, followed 
by IFA+PBS as second injection and PBS as third injection. Four groups of 5-7 mice 
were inoculated with 25mg, 50mg, 75mg, or 100mg of GST-LTXFIM in IFA. Booster 
injections were given as described above. All mice were bled from the retro-orbital sinus 
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nine days after the final immunization. After serum separation, all samples were stored at 
-80oC.  
Evaluation of antibody response 
      A capture ELISA using mouse monoclonal antibody MAb Ltx35 (10) was performed 
to determine anti- leukotoxin antibody titers in rabbits. In brief, 96-well plates (Immulon 
2HB, Dynex Technologies Inc, Chantilly, VA) were coated with MAb Ltx35 in PBS 
(10mg/ml), washed four times with PBS-0.05% Tween 20 (PBS-T) and blocked for 30 
minutes at 37oC in PBS-T. Native leukotoxin was prepared from culture supernatant of 
M. haemolytica as previously described (24), and was added to the wells at a previously 
determined optimum dilution of 1:100 and incubated for one hour at 37oC. After washing 
four times with PBS-T, plates were incubated for 2 h at 37oC with two-fold serial 
dilutions of serum from immunized animals. All serum dilutions were made in PBS-T. 
Plates were washed four times in PBS-T, incubated with secondary antibody (peroxidase 
conjugated goat anti-Rabbit IgG) for 1 h and developed by adding 100 ml of substrate 
solution containing 2,2’-azino di-ethylbenzothiazoline-6-sulfonic acid (ABTS, Sigma 
Chemical Company, St Louis, MO) and hydrogen peroxide. The A405 was measured in an 
EIA reader (BIO-TEK Instruments, Winooski, VT). The titers were determined as the 
reciprocal of the highest dilution of serum that gave an absorbance reading three times 
the conjugate control. For measuring antibodies in mice, leukotoxin was captured with 
ammonium sulfate precipitated rabbit polyclonal anti- leukotoxin serum (1/2000 dilution) 
and peroxidase conjugated rabbit anti-mouse IgG was used as the secondary antibody. 
Anti-FIM N antibodies were measured by ELISA as previously described (14).  
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Leukotoxin Neutralization Assays  
          Leukotoxin neutralization activity of serum was analyzed by a colorimetric 
cytotoxicity assay using tetrazolium dye (MTT) and BL-3 cells as previous ly described 
(27, 29).  Initially, native leukotoxin, prepared from culture supernatant of M. 
haemolytica was titrated using BL-3 cells to determine the toxin potency. One toxin unit 
was defined as the dilution of leukotoxin that killed 50% of the target cells. Heat 
inactivated (56oC for 30 minutes) serum samples diluted in RPMI-1640 were mixed with 
15 units of leukotoxin (optimal concentration was determined by titration) for 30 minutes 
at 4oC in triplicate wells of a 96 well plate. BL-3 cells (6.25 x104 /well) were added to the 
plates and incubated for 45 minutes at 37oC with 5% CO2. MTT (10mg/ml in RPMI 
1640) was added and incubated for 4 hours. The optical density (A562) was measured 
after lysing the cells with acid alcohol (0.4N HCl in isopropanol). The percentage of 
leukotoxin neutralization in each sample was calculated as described by Vega et al. (30) 
by using the formula:  
   {1-[(OD of the serum treated cells - OD of leukotoxin plus serum treated cells) / (OD of 
untreated cell control - OD of leukotoxin treated cells)]} x100. A cut-off value of 50% 
neutralization was considered positive for end point determination. Neutralization titers 
were determined for rabbit sera using two-fold serial dilutions. All mouse sera were 
analyzed at single dilutions of 1:60, 1:200 and 1:600. Like dilutions from each individual 
mouse were tested on a single day with same batch of cells and leukotoxin. 
  Statistical analyses 
        Statistical analyses were done using Statistical Analysis Software (SAS version 8) by 
the General Linear Model (GLM) procedure. The significance of differences between 
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groups for ELISA titers and leukotoxin neutralization activity was determined by 
Student’s t-tests. The data are expressed as mean +/- standard error of mean.  P values < 
0.05 were considered significant. 
Results 
Plasmid construction, recombinant protein expression and purification  
        The plasmids, pGEX-LTBE, pGEX-LTFIM, pGEX-FIM and pGEX-LTGST, were 
constructed in this study (Table 1, Appendix). Each plasmid encoded the GST gene 
downstream of a tac promoter and also had either a gene fragment (nucleotides 2673-
3336) encoding the carboxy-terminal portion of leukotoxin A, the 534 bp fragment 
(nucleotides 90-624) of the fim N gene, or both. Plasmid, pGEX-LTGST, had a second 
copy of a truncated GST gene cloned downstream from the leukotoxin fragment. All the 
genes were inserted in the correct reading frame as determined by DNA sequence 
analysis.  
        Each of the plasmids expressed recombinant protein in E. coli BL21-Gold after IPTG 
induction as determined by SDS PAGE and Western blots (Figure 1, Appendix). The 
stained polyacrylamide gels of whole-cell lysates showed prominent bands corresponding 
to the predicted molecular weights of the expected recombinant proteins (48.7 kD for 
GST-FIM, 53.5 kD for GST-LTX, 73.2 kD for GST-LTXFIM and 74.5 kD for GST-
LTXGST). Recombinant proteins, GST-LTX, GST-LTXFIM and GST-LTXGST, were 
recognized in Western blots by leukotoxin-neutralizing monoclonal antibodies MAb 
Ltx35, MAb Ltx4 and MAb Ltx2 (10). Monoclonal antibodies, BPA10, BPA5, and 
BPH2, specific for serotypes 2 fimbrial monomers of B.  pertussis (kindly provided by M 
Brennan, FDA ), reacted in Western blots with GST-FIM and GST-LTXFIM  
 155 
      The majority of GST-LTXFIM and GST-FIM proteins were isolated from insoluble 
cell lysate fractions and required purification under denaturing condition. GST-LTX was 
recovered from soluble cell lysate fractions and was initially purified in non-denaturing 
conditions. However, all protein preparations used for immunization were purified under 
denaturing conditions by the same procedure. Upon dialysis, GST-FIM and GST-
LTXFIM formed precipitates; whereas, GST-LTX did not. Purified recombinant fusion 
proteins migrated to their predicted molecular weights in SDS-PAGE gels (Fig 2). The 
SDS-PAGE banding pattern of GST-LTXFIM was unchanged, showing no signs of 
degradation after storage at -80oC for up to one year. On Western blots, the stored GST-
LTXFIM retained its reactivity to MAb Ltx35; whereas, GST-LTX did not (Figure 3). 
GST-LTX produced varying patterns of low molecular weight banding, suggestive of 
protein degradation, in different preparations  
Antibody responses in Rabbits 
      Groups of two or three rabbits were immunized with chimeric proteins, GST-
LTXFIM, GST-LTX, and GST-FIM. Native leukotoxin and HTFIM were used as ELISA 
antigens. HTFIM was used instead of the homologous antigen in ELISA to avoid 
reactivity with anti-GST antibodies. Pre-immune sera had no detectable anti- leukotoxin 
or anti- HTFIM antibodies. Rabbits (n=3) immunized with GST-LTXFIM had higher 
average ELISA titers (70,300 +/- 17, 100) against native leukotoxin than rabbits (n=3) 
immunized with GST-LTX (38,900  +/- 500). However, anti-HTFIM titers were lower in 
rabbits immunized with GST-LTXFIM  (4200 +/- 1000) than those of rabbits (n=2) 
immunized with GST-FIM alone (23, 000 +/-1400). Rabbits immunized with GST-FIM 
did not produce detectable antibodies reactive with native leukotoxin and rabbits 
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immunized with GST-LTX did not produce detectable HTFIM reactive antibodies. 
Leukotoxin neutralization titers in the BL-3 cytotoxicity assay were higher in rabbits 
immunized with GST-LTXFIM (340+/-130) compared to those immunized with GST-
LTX (120 +/-15). The differences observed in ELISA and leukotoxin neutralization titers 
were not statistically analyzed due to the low sample size. Rather, the rabbit study 
provided preliminary data for a mouse study performed with larger groups of animals. 
Antibody response in mice  
        The immunogenicity of LTX fusion proteins and adjuvant combinations were further 
evaluated in mice. The anti- leukotoxin IgG titers were determined for all individual mice 
(Figure 4A). All groups immunized with GST-LTXFIM produced significantly higher 
anti- leukotoxin antibody responses compared to groups similarly immunized with GST-
LTX (p< 0.01). The anti- leukotoxin ELISA titers of control mice were < 20. The group 
of mice immunized with GST-LTXFIM in CFA had the highest anti- leukotoxin ELISA 
titers and was significantly different from all other groups (P<0.01). The anti- leukotoxin 
ELISA titers of mice immunized with GST-LTXFIM in IFA was not significantly 
different from those similarly immunized with same antigen that had been stored at -80oC 
for six months (p>0.05). However, anti- leukotoxin ELISA titers of these two groups were 
significantly higher than GST-LTX in CFA (p<0.05). Anti- leukotoxin ELISA titers were 
significantly lower in groups immunized with GST-LTXGST in IFA than groups 
immunized with GST-LTXFIM either in IFA (p< 0.01) or CFA (p<0.001). The mice 
immunized with GST-LTX without adjuvant and stored GST-LTX had the lowest anti-
leukotoxin ELISA titers.  
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        The percentage of leukotoxin activity neutralized by each individual serum sample at 
a screening serum dilution of 1:60, 1:200 and 1:600 was determined. The mean 
leukotoxin neutralization activity of serum from individual groups of mice and the 
number of animals which had a neutralization activity greater than 50% are shown in 
Figure 4B. All the groups immunized with GST-LTXFIM induced significantly higher 
leukotoxin neutralization activity compared to groups similarly immunized with GST-
LTX.  At the 1:60 dilution, serum from 25 out of 27 mice immunized with GST-LTXFIM 
had leukotoxin neutralization activity greater than 50%, whereas, only 11out of 27 mice 
in GST-LTX groups had leukotoxin neutralization activity greater than 50%. Out of 27 
mice immunized with GST-LTXFIM, 11 were positive for neutralization activity at a 
serum dilution of 1:200 and six were positive at a serum dilution of 1:600 (data not 
shown). By contrast, in mice immunized with GST-LTX, 3 out of 27 mice at 1:200 serum 
dilution and none at 1:600 had leukotoxin neutralization activity greater than 50% (data 
not shown). None of the control animals had leukotoxin neutralization activity greater 
than 50%. Neutralization activity was statistically analyzed for each group at the 1:60 
serum dilution. There was no significant difference in neutralization activity of sera from 
mice immunized with freshly prepared GST-LTXFIM in CFA, IFA or PBS, and mice 
immunized with GST-LTXFIM that had been stored at -80oC for 6 months (p>0.05). 
Mice immunized with GST-LTX in CFA had the highest anti- leukotoxin antibody 
response among the GST-LTX groups. There was no significant difference in leukotoxin 
neutralization activity between groups immunized with GST-LTX in IFA, stored GST-
LTX in IFA and the control groups given CFA +PBS (p>0.05). The GST-LTX /CFA 
combination was the only GST-LTX preparation that was able to induce a leukotoxin-
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neutralizing antibody response which was comparable to those produced by GST-
LTXFIM antigens. Leukotoxin neutralization activities of sera from mice immunized 
GST-LTXGST in IFA was also significantly lower than those of sera from mice 
immunized with GST-LTXFIM in CFA (p<0.01), IFA (p< 0.05) and PBS (p<0.05). 
However, leukotoxin-neutralizing activity of sera from mice immunized with GST-
LTXGST was not significantly higher than from those immunized with GST-LTX in 
CFA (p>0.8), IFA (p>0.05) or PBS (p>0.6). Strong correlation between anti- leukotoxin 
ELISA titers and leukotoxin neutralization activity was observed in groups immunized 
with GST-LTXFIM (r = 0.60818, P = 0 .0008, n=27) but not in groups immunized with 
GST-LTX (r = 0.35196, P = 0.0718, n=27). Groups of mice immunized with 25mg, 50mg, 
75mg and 100mg of GST-LTXFIM in IFA, did not have significant differences in anti-
leukotoxin IgG titers or leukotoxin neutralization activity (Figure 5). 
Discussion  
        Leukotoxin is a major virulence factor in M. haemolytica- induced pneumonia of 
feedlot cattle (3, 6, 8, 29, 31). There is a significant correlation between high levels of 
leukotoxin-neutralizing antibodies and a reduction in pneumonic lesion scores in 
naturally and experimentally infected cattle (19, 20, 21, 25, 26, 27, 28). However, the 
instability of leukotoxin and the resulting difficulty in its purification have limited its use 
as an additive component in vaccines (7). This report demonstrates that immunization 
with a fusion protein consisting of the carboxy-terminal peptide of leukotoxin and FIM N 
induced high levels of leukotoxin-neutralizing antibodies in laboratory animals. Unlike 
GST-LTX, the chimeric GST-LTXFIM antigen was stable on storage at -80o C and 
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induced high levels of leukotoxin-neutralizing antibody even without the use of 
adjuvants.  
        The leukotoxin neutralization assay is very sensitive; variations in leukotoxin potency 
and the sensitivity of target cells can greatly influence the outcome of the assay. It has 
been reported that the coefficient of variation of this assay, performed on separate days, 
ranged from 0-36% (30). In this study, the effects of day to day variations were 
minimized by testing the serum from each individual on a single day using a single vial 
of leukotoxin and the same batch of BL-3 cells. End points were determined for serial 
dilutions of rabbit sera. The minimal dilution at which each individual mouse sample 
could be compared was 1:60 and the assay at this dilution was performed twice on two 
different days.  Leukotoxin neutralization activity was also determined at 1:200 and 
1:600 serum dilutions. It was estimated that the leukotoxin neutralization titers of GST-
LTXFIM immunized mice were between 60 and 600. These levels were consistent with 
the titers seen in rabbits and were as high as reported leukotoxin neutralization titers in 
cattle (26, 27, 30). In GST-LTX groups, more than half of the individual serum samples 
may have titers less than 60. 
        Mice immunized with antigens containing GST-LTXFIM consistently produced 
higher levels of anti- leukotoxin antibodies than mice similarly immunized with LTX 
antigens lacking FIM N.  Inclusion of CFA in the GST-LTXFIM antigen significantly 
increased the leukotoxin antibody response as measured by ELISA with native 
leukotoxin as antigen, but did not significantly affect leukotoxin-neutralizing antibody 
response in the BL-3 cell cytotoxicity assay. Doses of GST-LTXFIM antigen ranging 
from 25mg - 100mg produced equivalent leukotoxin-neutralizing antibody responses. 
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These observations suggest that stringent immunization protocols (eg. high dose, and 
adjuvants) may not be required to elicit maximum leukotoxin-neutralizing antibody 
responses when the chimeric GST-LTXFIM protein is used. It was previously observed 
that a recombinant fusion of leukotoxin and interleukin-2 produced an enhanced 
lymphocyte proliferation response but did not enhance anti- leukotoxin antibody 
production (13).  
         It was observed that the LTX-FIM immunogen, regardless of the adjuvant used, 
consistently induced higher levels of leukotoxin- neutralizing activity in all groups and 
that serum samples from mice immunized with LTX-FIM immunogen neutralized at least 
50% of the cytotoxicity of 15 units of leukotoxin at dilutions where other LTX 
immunogens lacking FIM N lost this capacity. The active toxin concentration used was 
intentionally chosen to be several fold higher than normally used (15 vs 1-3 units) to 
eliminate variability in cytotoxicity. Possibly more significant, was a much closer 
statistical correlation between anti- leukotoxin ELISA titers and leukotoxin neutralizing 
activity in sera from LTX-FIM immunized mice than in the sera from mice immunized 
with LTX lacking FIM. The strong suggestion is that the FIM fusion enhances production 
of potentially protective (neutralizing) antibodies more so than fusions lacking FIM N.  A 
stable subunit fragment of leukotoxin, such as GST-LTXFIM might provide a basis for 
an ELISA with greater specificity for protective, neutralizing antibodies and would be of 
great aid to vaccine evaluation. 
       The mechanism of enhancement of anti- leukotoxin antibody production following 
fusion of FIM N to the carboxy-terminus of GST-LTX is unknown but may simply 
reflect protection of exposed LTX epitopes against degradation. In vitro and in vivo 
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degradation or instability of neutralizing epitopes at the carboxy-terminus of GST-LTX 
may explain the lower responses to GST-LTX antigen preparations. This hypothesis is 
supported by the observation that GST-LTX no longer reacted with MAb Ltx35, a 
leukotoxin-neutralizing monoclonal antibody, after storage at -80oC. The frequent 
appearance of multiple protein bands in GST-LTX preparations is also suggestive of 
product deterioration. It is possible that the purification process altered the protein’s 
conformation in a fashion that would hasten proteolytic degradation. However, fresh 
preparations of GST-LTX consistently reacted with MAb Ltx35. It is likely that 
degradation occurred at the time of processing or after thawing, since little physical or 
enzymatic activity would be expected during storage at -80oC. The difference in the 
number of epitopes in these antigens does not appear to be a significant factor in these 
observations, since the molar proportion of LTX epitopes was approximately one third in 
the GST-LTXFIM antigen compared to GST-LTX. Also, the fusion of GST, a peptide of 
similar size to FIM N, to the carboxy- terminus of GST-LTX, did not effectively enhance 
the anti- leukotoxin antibody response. Therefore, it is probable that secondary or tertiary 
protein structure interactions in GST-LTXFIM provided greater LTX epitope exposure. 
These interactions may have been absent in GST-LTX or GST-LTXGST. FIM N is 
highly immunogenic; its hydrophobic nature and T-cell epitopes might have aided in 
enhanced antigen presentation and antibody response. The general insolubility and 
resistance of fimbrial proteins to chemical and proteolytic degradation (15) might also 
have predictably contributed to the enhanced immune response. 
      Vaccines incorporating live M. haemolytica organisms or whole toxin may produce 
febrile reactions and result in a lower generalized immune response (7). A stable 
 162 
leukotoxin subunit vaccine component would seem to hold great promise for improving 
bovine health. The immunogenicity of LTX- FIM N recombinant protein in cattle and 
role of FIM N as an immunomodulatory antigen merit further study. 
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    Figure 1 
 SDS-PAGE and Western blot of E. coli whole-cell lysates harboring recombinant 
plasmids. 
                    A. SDS-PAGE- Whole-cell lysates of E. coli (BL21-Gold) expressing the recombinant 
proteins were separated on a 10% polyacrylamide gel and stained with Pierce Gel 
Code Blue Stain reagent. Pre-stained molecular weight markers in kDa (Bio-Rad) 
(lane 1), Native leukotoxin (lane 2), GST-LTX (lane 3), GST-LTXFIM (lane 4), GST-
FIM (lane 5), GST-LTXGST (lane 6). Arrows indicate prominent bands corresponding 
to the predicted molecular weight of expected recombinant proteins. 
    B. Western blot- Proteins were electro-transferred on to a nitrocellulose membrane and 
probed with anti- leukotoxin monoclonal antibody, MAb Ltx35. 
 170 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      1          2      3      4       5      6 
A  205 
110 
77 
  43.3 
31.6 
 1        2      3       4      5       6  
B 205 
110 
 
77 
 
 
 
43 
31.6 
 171 
Figure 2  
   SDS-PAGE of recombinant proteins used for immunization. 
Recombinant proteins were purified by affinity chromatography. Approximately 15mg of 
each protein was electrophoresed on a 10% polyacrylamide gel and stained with Pierce 
Gel Code Blue Stain reagent. Pre-stained molecular weight markers in kDa (Bio-Rad) 
(lane 1), GST-LTXFIM (lane 2), GST-LTX (lane 3), GST-FIM (lane 4). 
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Figure 3 
SDS-PAGE and Western blot of recombinant GST-LTX and GST-LTXFIM stored at -
80oC for 1 year.  
A. SDS-PAGE -Approximately 15mg of each protein was electrophoresed on a 10% 
polyacrylamide gel and stained with Pierce Gel Code Blue Stain reagent. Pre-stained 
molecular weight markers in kDa (Bio-Rad) (lane 1) GST-LTX (lane 2) GST-LTXFIM 
(lane 3) 
B. Western blot. The proteins were electro-transferred to nitrocellulose and probed with 
anti- leukotoxin antibody MAb Ltx35.  
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    Figure 4 
               Antibody response of individual groups of mice immunized with recombinant proteins 
               Mice were immunized with three successive injections of antigens on days1, 14 and 35 
as described in text. (1). GST-LTXFIM in CFA, (2). GST-LTX in CFA, (3). GST-
LTXFIM in IFA, (4). GST-LTX in IFA, (5). GST-LTXFIM in PBS, (6). GST-LTX in 
PBS, (7). GST-LTXGST in IFA, (8). GST-LTXFIM in IFA (stored), (9). GST-LTX in 
IFA (stored), (10). Control (CFA+PBS). The composition of first immunization was as 
given above. The second dose of antigen had similar adjuvant composition but CFA was 
substituted with IFA, and antigen alone in PBS was used for third dose in each group. 
Dark bars represent LTX with  
               FIM N, while lighter bars represent LTX immunogens without FIM N. The significance 
of differences in responses from immunized groups was analyzed by Student’s t-test. A  
p-value <0.05 was considered significant. Presence of asterisk indicates the values are 
significantly different from control animals. (* = p< 0.001., ** = p< 0.01., *** = 
p<0.05). 
  A.  Mean anti- leukotoxin IgG ELISA titers +/- SEM is reported.  
    B.  Leukotoxin neutralization activity is expressed as the percentage of neutralization of 
15 units of leukotoxin by a 1:60 dilution of serum measured on two different days. 
The mean  +/-SEM is reported. The number shown above each bar is the number of 
mice that had greater than 50% leukotoxin neutralization activity out of the total 
number tested. 
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Figure 5 
 Effect of GST-LTXFIM antigen dose on anti- leukotoxin antibody response in mice. 
               Mice were inoculated I.P. on days 0, 14, and 35 with GST-LTXFIM. The first two doses 
were in IFA and last in PBS. The significance of differences in responses from 
immunized groups was analyzed by Student ’s t-test. A p-value <0.05 was considered 
significant. Presence of asterisk indicates the values are significantly different from 
control animals. (* = p< 0.001., ** = p< 0.01., *** = p<0.05). 
            A.  Mean anti- leukotoxin IgG titers +/- SEM.  
         B.  Leukotoxin neutralization activity is expressed as the percentage of neutralization of 
15 units of leukotoxin by a 1:60 dilution of serum. The mean +/- SEM is reported. 
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TABLE 1. Descriptions of plasmids used in this study 
Plasmid                               Description 
PCR 2.1                         TA Cloning vector (Invitrogen) Ampicillin resistance                                    
 
pGEX-5X-1                   GST gene fusion expression vector (Pharmacia). 
 
PCR2-FIM                     fim N gene with regulatory and coding                      
                                        sequence in EcoRI and HindIII  sites of  PCR 2.1 (14) 
  
pGEX-FIM                     fim N gene coding sequence without the putative signal sequence 
in   EcoRI and XhoI sites of pGEX-5X-1 (this study) (GST-
FIM)A 
                                       
pGEX-LT FUSION         Leukotoxin A gene nucleotides encoding carboxy-terminal   
amino acids  713-939 in  EcoRI and XhoI sites of  pGEX-4T-1 
(16) 
 
pGEX-LTBE                  Leukotoxin A gene nucleotides encoding carboxy-terminal  
aminoacids 719-939 from pGEX LT FUSION in BamH I and 
EcoRI sites of pGEX- 5X-1 (this study) (GST-LTX)A 
 
pGEX-LTFIM               Leukotoxin A gene fragment in BamHI and EcoRI sites and fim 
N gene in EcoRI and XhoI sites of pGEX-5x-1.(this study)  (GST-
LTXFIM )A 
                         
pGEX-LTGST              GST gene fragment cloned downstream to LTX in XhoI site of  
                                       pGEX-LT FUSION. (This study) (GST-LTXGST)A 
                   
pPROEXTM-HT-FIM    fim N gene without the signal sequence in  
                                        pPROEXTM HT (Gibco/BRL) (HTFIM)A  (14) 
 
 
 
 
Letters in the parenthesis with superscript A indicate the name of the protein expressed 
by the plasmids. 
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                                                  PART 5 
                              General Summary
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Summary 
      The first part of this research work was focused on identifying constitutive 
promoters suitable for heterologous antigen expression in B. bronchiseptica. This 
investigation resulted in isolation and characterization of a promoter region related to 
heat shock gene family. The promoter was active in vitro and was able to induce high-
level expression of GFP.  The taco promoter, which is an E. coli derived promoter, was 
also active inB. bronchiseptica. Low-level activity of Fim N promoter was detected in 
Bvg+ strains of B. bronchiseptica indicating that this promoter was Bvg-regulated. The 
low level activity of this promoter was enhanced by growth in a minimal salt media and 
may be further enhanced by manipulating the C-stretch region of the promoter. The 
promoter we identified belonged to the family of heat shock genes. These genes are 
usually induced under stress conditions. However this study did not identify any 
induction condition for this promoter region.  
      The plasmid used to express heterologous antigen in B. bronchiseptica was originally 
isolated from B. bronchiseptica. However, the reconstructed plasmid was not stable in 
vivo or in vitro under non-selective condition. The foreign DNA engineered into the 
plasmid and heterologous antigen expression may be the factors contributing to plasmid 
instability. Identification of moderately active promoters, construction of more stable 
plasmids, and chromosomal integration of the foreign gene can be pursued 
       In the second part of the study, we expressed a non-toxic protective P. multocida 
toxin fragment (PMTCE) in B. bronchiseptica under the control of the promoter we 
identified. However, the level of expression of this protein was very low. Intranasal 
inoculation with B. bronchiseptica expressing PMTCE did not induce a PMT-specific 
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antibody response. Mucosal and systemic antibody response was generated against B. 
bronchiseptica. However, four intranasal inoculations at 14 day intervals with B. 
bronchiseptica expressing GFP induced a mucosal and systemic immune response 
against GFP. Factors like differences in the antigenicity, low level expression and 
plasmid instability might have contributed to the difference in immune response to these 
two heterologous antigens expressed by B. bronchiseptica. Improvement in plasmid 
stability and antigen expression is required to improve the system. 
      The third part of this study evaluated the immune response to a chimeric protein 
created by fusing the FIM N protein of B. bronchiseptica and an unstable protective 
fragment of Mannheimia haemolytica leukotoxin. Immunization of mice with this 
chimeric protein elicited stronger anti- leukotoxin antibodies than similar immunization 
with protein, which lacks the FIM N. Also, the molecular chimerization improved the 
stability of the leukotoxin fragment. This protein may be an efficient vaccine candidate to 
prevent M. haemolytica-induced shipping fever in feedlot cattle. Adhesins are excellent 
targets for vaccine development and they have been explored as potential vehicles for 
delivery of heterologous antigens. FIM N protein may be an effective carrier for 
heterologous antigen delivery in B. bronchiseptica. However, the immunomodulatory 
property of FIM N needs further investigation.  
       Atrophic rhinitis is a disease of significant economic importance to US agriculture. 
The involvement of B. bronchiseptica and P. multocida in this disease condition is well 
documented.  This study provides basis for the development of an improved, single 
component vaccine against atrophic rhinitis. However, optimization of antigen expression 
to induce an effective immune response is required. Further genetic modification to 
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inactivate the important virulence factors of B. bronchiseptica has to be pursued. Since B. 
bronchiseptica can colonize the respiratory tract of wide variety of host species, potential 
for applying this model to other species and diseases is great. Utilizing the benign 
colonization of B. bronchiseptica to deliver a protective antigen will be a potent way to 
induce a mucosal immune response at the respiratory tract mucosa. 
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